<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Wiley</publisher>
				<availability status="unknown"><p>Copyright Wiley</p>
				</availability>
				<date type="published" when="2003-11-19">2003-11-19</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Dominique</forename><surname>Figarella-Branger</surname></persName>
							<email>dominique.figarella-branger@medecine.univ-mrs.fr</email>
							<affiliation key="aff0">
								<orgName type="department">Faculte ´de Me ´decine Timone</orgName>
								<orgName type="laboratory">Laboratoire de Biopathologie Nerveuse et Musculaire</orgName>
								<orgName type="institution">Universite ´de la Me ´diterrane ´e</orgName>
								<address>
									<addrLine>27 Bd Jean Moulin</addrLine>
									<postCode>3281), 13385</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Service d&apos;Anatomie Pathologique et de Neuropathologie</orgName>
								<orgName type="institution">Ho ˆpital de la Timone</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Ho ˆpitaux de Marseille</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Muriel</forename><surname>Civatte</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculte ´de Me ´decine Timone</orgName>
								<orgName type="laboratory">Laboratoire de Biopathologie Nerveuse et Musculaire</orgName>
								<orgName type="institution">Universite ´de la Me ´diterrane ´e</orgName>
								<address>
									<addrLine>27 Bd Jean Moulin</addrLine>
									<postCode>3281), 13385</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Service d&apos;Anatomie Pathologique et de Neuropathologie</orgName>
								<orgName type="institution">Ho ˆpital de la Timone</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Ho ˆpitaux de Marseille</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Catherine</forename><surname>Bartoli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculte ´de Me ´decine Timone</orgName>
								<orgName type="laboratory">Laboratoire de Biopathologie Nerveuse et Musculaire</orgName>
								<orgName type="institution">Universite ´de la Me ´diterrane ´e</orgName>
								<address>
									<addrLine>27 Bd Jean Moulin</addrLine>
									<postCode>3281), 13385</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Service d&apos;Anatomie Pathologique et de Neuropathologie</orgName>
								<orgName type="institution">Ho ˆpital de la Timone</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Ho ˆpitaux de Marseille</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jean-Fran�ois</forename><surname>Pellissier</surname></persName>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">by University Of Illinois At Urbana Champaign</orgName>
								<address>
									<addrLine>Wiley Online Library on [06</addrLine>
									<country>03</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">by University Of Illinois At Urbana Champaign</orgName>
								<address>
									<addrLine>Wiley Online Library on [06</addrLine>
									<country>03</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Muscle &amp; Nerve</title>
						<title level="j" type="abbrev">Muscle Nerve</title>
						<idno type="ISSN">0148-639X</idno>
						<idno type="eISSN">1097-4598</idno>
						<imprint>
							<publisher>Wiley</publisher>
							<biblScope unit="volume">28</biblScope>
							<biblScope unit="issue">6</biblScope>
							<biblScope unit="page" from="659" to="682"/>
							<date type="published" when="2003-11-19" />
						</imprint>
					</monogr>
					<idno type="MD5">DAB6C975110A32C7E4E5F5FB3DD22AF2</idno>
					<idno type="DOI">10.1002/mus.10462</idno>
					<note type="submission">Accepted 13 June 2003</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>CAM, cell adhesion molecules</term>
					<term>CC, ␤ chemokines family</term>
					<term>CCR, CC-chemokine receptor</term>
					<term>CK, creatine kinase</term>
					<term>CXC, ␣ chemokines family</term>
					<term>CXCR, CXC-chemokine receptor</term>
					<term>CX3C, ␥ chemokines family</term>
					<term>CX3CR, CX3C-chemokine receptor</term>
					<term>DM, dermatomyositis</term>
					<term>ICAM, intercellular adhesion molecule</term>
					<term>IFN, interferon</term>
					<term>IL, interleukin</term>
					<term>IM, inflammatory myopathies</term>
					<term>IVIg, intravenous immunoglobulin</term>
					<term>LFA-1, lymphocyte activating factor 1</term>
					<term>MAC, membranolytic attack complex</term>
					<term>MCP, monocyte chemotactic protein</term>
					<term>MHC, major histocompatibility complex</term>
					<term>MIP, macrophage inflammatory protein</term>
					<term>PECAM-1, platelet endothelial cell adhesion molecule-1</term>
					<term>PM, polymyositis</term>
					<term>RANTES, regulated upon activation, normal T-cell expressed and secreted</term>
					<term>RT-PCR, reverse transcriptase-polymerase chain reaction</term>
					<term>s-IBM, sporadic inclusion-body myositis</term>
					<term>SLe x , sialyl Le x</term>
					<term>SOCS, suppressor of cytokine signaling</term>
					<term>STAT, signal transducers and activators of transcription</term>
					<term>TCR, T-cell receptor</term>
					<term>T H , T helper</term>
					<term>TNF, tumor necrosis factor</term>
					<term>TNF-R, TNF receptor</term>
					<term>VCAM, vascular cellular adhesion molecule</term>
					<term>VLA4, very late antigen 4</term>
					<term>XC, ␦ chemokines family</term>
					<term>XCR, XC-chemokine receptor cell adhesion molecules</term>
					<term>cytokines</term>
					<term>dermatomyositis</term>
					<term>inflammatory myopathies</term>
					<term>pathogenesis</term>
					<term>polymyositis</term>
					<term>sporadic inclusion-body myositis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The inflammatory myopathies include dermatomyositis (DM), polymyositis (PM), and sporadic inclusion-body myositis (s-IBM). In DM, the main immune effector response appears to be humoral and directed against the microvasculature, whereas in both PM and s-IBM, cytotoxic CD8 ϩ T cells and macrophages invade and eventually destroy nonnecrotic muscle fibers expressing major histocompatibility complex class I. The need for more specific and safer therapies in inflammatory myopathies has prompted researchers to better decipher the molecular events associated with inflammation and muscle fiber loss in these diseases. The complex specific migration of leukocyte subsets to target tissues requires a coordinated series of events, namely activation of leukocytes, adhesion to the vascular endothelium, and migration. Cell adhesion molecules (CAM) and chemokines play a major role in this multistep process. In addition, cytokines by stimulating CAM expression and orchestrating T-cell differentiation also influence the immune response. This review focuses on recent advances in defining the molecular events involved in leukocyte trafficking in inflammatory myopathies. Specific topics include a concise summary of clinical features, pathological findings and immunopathology observed in inflammatory myopathies, background information about cytokines, chemokines and cell adhesion molecules, and the expression of these molecules in inflammatory myopathies.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The inflammatory myopathies, including dermatomyositis (DM), polymyositis (PM), and sporadic inclusion-body myositis (s-IBM), are a heter-ogeneous group of muscle disorders that are defined by acquired muscle weakness and inflammatory infiltrates of muscle tissue. <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b75">76,</ref><ref type="bibr" target="#b127">128</ref> There is evidence that these diseases are secondary to an autoimmune process that probably results in muscle injury. However, the antigens eliciting the immune responses still remain unknown. Each category of inflammatory myopathies is characterized by clinical, morphological, and immunopathological features. <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b104">105</ref> Inflammatory myopathies are currently treated with immunosuppressive or immunomodulating drugs, but a number of patients (especially with s-IBM) are unresponsive or are left with reduced muscle function. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b63">64,</ref><ref type="bibr" target="#b120">121</ref> The need for more specific and safer therapies has prompted researchers to better decipher the molecular events associated with inflammation and muscle fiber loss in inflammatory myopathies.</p><p>The complex specific migration of leukocyte subsets to target tissues is oriented by interactions of leukocytes with the endothelium. During the last 15 years, understanding of the role of cytokines, chemokines, and cell adhesion molecules in the trafficking of inflammatory cells has grown substantially, and it has been shown that nonimmune cell types, such as skeletal muscle cells, actively contribute to inflammation by synthesizing such molecules. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b107">108,</ref><ref type="bibr" target="#b116">117,</ref><ref type="bibr" target="#b126">127</ref> This review focuses on recent advances in defining the molecular events involved in leukocyte trafficking in inflammatory myopathies. Specific topics include a concise summary of clinical features, pathological findings and immunopathology observed in inflammatory myopathies, background information about cytokines, chemokines, and cell adhesion molecules, and the expression of these molecules in inflammatory myopathies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IDIOPATHIC INFLAMMATORY MYOPATHIES Clinical Features.</head><p>Dermatomyositis. DM occurs at any age with two peaks of higher incidence: 5-15 (juvenile DM) and 45-65 years. The female-to-male ratio is 2:1. In addition to proximal and symmetrical muscle weakness, patients develop characteristic skin changes.These include heliotropic erythema of the eyelids, cheeks, and trunk, chronic skin lesions including pigmentation abnormalities, erosion of the knuckles, and subcutaneous calcifications in later stages (mainly juvenile DM). Changes around the fingernails, consisting of cuticular overgrowth and nail-bed telangiectasia are frequent findings. Raynaud's phenomenon as well as cutaneous or intestinal ulcerations as a sign of generalized vascular injury may be observed. <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b64">65</ref> In children, cardiac involvement may occur.</p><p>The incidence of malignancies in patients over 40 years of age is much higher with DM than with PM. Associated malignancies are not observed in juvenile DM. Overlap syndromes may be observed as in PM, but there is no association with viral infections.</p><p>Laboratory studies may show an inflammatory syndrome, increased serum creatine kinase (CK) level, and myositis-specific auto-antibodies. Electromyogram typically shows alterations in the motor unit potentials and the appearance of abnormal muscle-fiber irritability. <ref type="bibr" target="#b32">33</ref> Polymyositis. PM occurs in adults, with a female predominance (2:1). There is proximal and symmetrical muscle weakness. Up to 50% of patients have muscle pains and arthralgias. Cardiac involvement may occur during all stages of the disease. Interstitial lung disease, often associated with anti-JO1 antibodies (directed against histidyl transfer RNA syn-thetase) suggests a poor prognosis and is observed in about 10% of patients.</p><p>PM may occur separately or in conjunction with other autoimmune diseases (overlap syndromes) such as scleroderma, Sjo ¨gren's syndrome, systemic lupus erythematosus or rheumatoid arthritis, and with viral infections, especially HIV or HTLV-I. <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b34">35</ref> The association of PM with various retroviruses resulting in disease immunopathologically identical to idiopathic PM suggests that retroviruses can trigger inflammatory myopathies. <ref type="bibr" target="#b32">33</ref> Associated malignancies, preceding or following the onset of PM, may be observed.</p><p>Laboratory studies may show an inflammatory syndrome, elevation of serum muscle enzymes (especially creatine kinase), and myositis-specific autoantibodies, but there is no evidence that these antibodies play a pathogenetic role in the disease. <ref type="bibr" target="#b127">128</ref> The antisynthetase antibodies may help to define the antisynthetase syndrome (myositis overlapping with polyarthritis, Raynaud's phenomenon, and interstitial lung disease). Electromyography typically shows a nonspecific myopathic pattern. <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b64">65</ref> Sporadic Inclusion-Body Myositis. This occurs in patients older than 50 years, with a male-to-female predominance (3:1). Patients with s-IBM have a unique pattern of selective muscle weakness that involves certain distal and proximal muscle groups. <ref type="bibr" target="#b63">64</ref> Asymmetrical involvement is frequent. The disorder can be associated with systemic autoimmune diseases in up to 15% of cases. In spite of being considered an inflammatory myopathy, patients do not respond to antiinflammatory therapies and the risk of patients becoming severely disabled and wheelchair-bound within 10 -15 years after onset is high. Some authors have suggested that s-IBM should no longer be grouped among the inflammatory myopathies. <ref type="bibr" target="#b125">126</ref> Laboratory studies are usually unhelpful: serum creatine kinase levels are moderately increased and erythrocyte sedimentation rate is normal in twothirds of patients. Electromyography typically shows a mixed myopathic and neurogenic pattern.</p><p>Pathological Findings and Immunopathology.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dermatomyositis.</head><p>Muscle biopsy in DM typically shows evidence for vascular injury. This includes endothelial alterations as shown by light and electron microscopic studies, tubuloreticular profiles in endothelial cells, thrombosis, and infarction <ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b49">50</ref> (Fig. <ref type="figure" target="#fig_0">1A,B</ref>).</p><p>Quantitative morphological analyses suggest that depletion of capillaries is one of the early changes in DM <ref type="bibr" target="#b82">83</ref> and may be observed before inflammatory changes. <ref type="bibr" target="#b46">47</ref> Microvascular deposition of C5b-9, the membranolytic attack complex (MAC) of the complement pathway, is detected on the endomysial capillaries early in the disease where it forms immunoreactive microthrombi <ref type="bibr" target="#b82">83</ref> (Fig. <ref type="figure" target="#fig_0">1D</ref>). Perivascular inflammatory exudates are mainly composed of macrophages, CD4 ϩ , and 〉 lymphocytes <ref type="bibr" target="#b48">49</ref> (Fig. <ref type="figure" target="#fig_0">1E,F</ref>). In addition, one major find- ing which is suggestive of DM, even in the absence of an inflammatory infiltrate, is perifascicular atrophy. It may be absent, however, especially in adult patients.</p><p>The mechanism leading to perifascicular atrophy is unclear. It is generally assumed that it reflects hypoperfusion of the fascicle. Interestingly, affected fibers share with regenerative fibers the expression of the neural cell adhesion molecule NCAM and its polysialylated isoform. <ref type="bibr" target="#b55">56</ref> In contrast to PM and s-IBM, class I MHC expression in DM is usually restricted to perifascicular fibers (atrophic or not) <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b54">55,</ref><ref type="bibr" target="#b76">77</ref> (Fig. <ref type="figure" target="#fig_0">1C</ref>).</p><p>Taken together, the data summarized above suggest that the main immune effector response in DM is humoral and directed against the endothelial cells of the microvasculature.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Polymyositis and Sporadic Inclusion-Body Myositis.</head><p>In both PM and s-IBM, muscle biopsy shows randomly distributed necrotic fibers undergoing phagocytosis, and regenerative fibers. The most salient feature common to both PM and s-IBM is endomysial inflammatory exudates and partial invasion of nonnecrotic muscle fibers (Fig. <ref type="figure" target="#fig_1">2A,C</ref>). It is for this reason that we have chosen to group PM and IBM together, although some pathological features are radically different in these two diseases.</p><p>In contrast to PM, muscle biopsy in s-IBM also shows rimmed vacuoles in muscle fibers filled with whorls of membranes and abnormal tubulo-filamentous inclusions measuring 14 -18 nm in diameter by electron microscopy. These filaments may also be observed within nuclei. Clusters of small-diameter angular fibers are observed as well as numerous mitochondrial changes. <ref type="bibr" target="#b53">54</ref> Numerous vacuolated fibers contain foci of amyloid deposits. Inclusions are immunoreactive with anti SMI-31, a monoclonal antibody that recognizes phosphorylated tau. Inclusions are also immunoreactive with antiubiquitin antibody and accumulate several proteins that accumulate in the brain of patients with Alzheimer's disease, such as ␤-amyloid precursor protein epitopes, ␤-amyloid, and presenilin1. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b120">121</ref> The observation that the s-IBM muscle-fiber immunohistochemical phenotype has features remarkably similar to those of the Alzheimer's disease brain are intriguing <ref type="bibr" target="#b8">9</ref> and raise new insights into the pathogenesis of the disease. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b120">121</ref> In PM and s-IBM, cytotoxic CD8 ϩ T cells and macrophages focally surround and invade nonnecrotic muscle fibers <ref type="bibr" target="#b7">8</ref> (Fig. <ref type="figure" target="#fig_1">2D</ref>). Up to 50% of the CD8 ϩ autoinvasive T cells express class II MHC suggesting that they are activated <ref type="bibr" target="#b47">48</ref> and the vast majority of the inflammatory CD4 ϩ and CD8 ϩ T cells express the RO isoform of the leukocyte common antigen CD45 and therefore, are memory T cells. All of the invaded fibers and numerous noninvaded fibers express increased amounts of class I MHC molecules <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b76">77</ref> on their cell surface membranes (Fig. <ref type="figure" target="#fig_1">2B</ref>) and some also express class II MHC. <ref type="bibr" target="#b50">51,</ref><ref type="bibr" target="#b117">118</ref> Interestingly, in PM, almost all muscle fibers strongly express class I MHC, whereas in s-IBM, the expression is higher in the fibers showing partial invasion or located near inflammatory exudates. <ref type="bibr" target="#b56">57,</ref><ref type="bibr" target="#b76">77</ref> In PM, a strong class I MHC expression may be observed on muscle cell surface membrane even in muscle biopsies devoid of inflammatory exudates <ref type="bibr" target="#b119">120,</ref><ref type="bibr" target="#b123">124</ref> (Fig. <ref type="figure" target="#fig_1">2E,F</ref>).</p><p>In contrast, skeletal muscle fibers do not constitutively express or display MHC molecules. Therefore it is logical to assume that a response mediated by class I MHC restricted cytotoxic T lymphocytes against antigens expressed on muscle fibers occurs in both PM and s-IBM. Consistent with this hypothesis are the findings observed by immunoelectron microscopy: CD8 ϩ T cells show spike-like processes that traverse the basal lamina and invade the sarcolemma of nonnecrotic muscle fibers <ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b48">49</ref> and CD8 ϩ T cells expanded from muscle of patients with different inflammatory myopathies (IM) show low but significant cytotoxicity against autologous myotubes. <ref type="bibr" target="#b65">66</ref> Moreover, recent findings support the concept that the autoinvasive CD8 ϩ T cells are specifically selected and clonally expanded in situ. They exhibit gene rearrangement of their T-cell receptor (TCR) and restricted amino acid sequences in the complementary determining region 3 (CDR3). <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b103">104</ref> In addition, clonal restriction of TCR expression has been shown to persist over time in s-IBM muscles. <ref type="bibr" target="#b3">4</ref> Interestingly, increased expression of the matrix metalloproteinases MMP-9 and MMP-2 have been reported in the nonnecrotic and class I MHC-expressing muscle fibers in PM and s-IBM, whereas the autoinvasive cytotoxic T cells expressed MMP-9. It is likely that the MMPs, by degrading the main component of the basal lamina, collagen IV, facilitate lymphocyte adhesion and enhance T-cell-mediated cytotoxicity. <ref type="bibr" target="#b25">26</ref> It has been suggested that several infiltrating cells in inflammatory myopathies have dendritic cell morphology and immunological properties.</p><p>The mechanisms leading to muscle fiber death in both PM and s-IBM are still a matter of debate. <ref type="bibr" target="#b64">65</ref> Briefly, two main mechanisms may occur. The first involves the secretion of the pore-forming protein perforin by the cytotoxic T cells. <ref type="bibr" target="#b62">63</ref> The second relies on the interaction of the Fas ligand that is upregulated during T-cell activation, with the apoptosisinducing Fas receptor on the target cell. Although some studies have reported that many muscle fibers in inflammatory myopathies express Fas, <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b58">59</ref> others have shown the expression of antiapoptotic molecules suggesting that muscle fibers are resistant to Fas-mediated injury. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b88">89,</ref><ref type="bibr" target="#b114">115,</ref><ref type="bibr" target="#b141">142</ref> In keeping with that finding is the lack of nuclear changes typical of apoptosis in muscle of affected patients. In addition, mechanisms of muscle fiber loss in s-IBM likely involves other mechanisms that will not be discussed here. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b120">121</ref> In spite of these results, the antigens eliciting the immune response as well as the putative immunological role of muscle cells are still unknown.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GENERAL MECHANISMS OF INFLAMMATION</head><p>The complex specific migration of leukocyte subsets to target tissues requires a coordinated series of events, namely activation of leukocytes, adhesion to the vascular endothelium, and migration. Cell adhesion molecules (CAM) and chemokines play a major role in this multistep process. In addition, cytokines by stimulating CAM expression and orchestrating T-cell differentiation also influence the immune response (Fig. <ref type="figure" target="#fig_2">3</ref>).</p><p>Cytokines. Cytokines are regulatory proteins secreted by white blood cells and a variety of other cells in the body. Most cytokines are simple polypeptides or glycoproteins with a molecular weight of 30 kDa or less. Constitutive production of cytokines is usually low or absent; production is regulated by various inducing stimuli at the level of transcription or translation. Cytokine production is transient and they mainly act locally by binding to the cell of their origin (autocrine) or to a neighboring target cell (paracrine). Cytokines bind to specific high-affinity cell surface receptors (Kd in the range 10 Ϫ9 to 10 Ϫ12 M). Many cytokine receptors can be grouped into families on the basis of common structural findings. <ref type="bibr" target="#b143">144</ref> Because of the tremendous efficiency of cytokines, their activities have to be tightly controlled. Endogenous cytokine inhibitors exist that interfere with the binding of the cytokine to its specific receptor. It is not surprising therefore that new therapeutic agents that may interfere with the binding of cytokines to their receptors have recently been developed.</p><p>Despite the identification of many structurally distinct cytokines (more than 150 cytokines have been cloned to date), they can be organized into groups that exhibit functional similarities on the basis of shared receptor utilization (Table <ref type="table" target="#tab_0">1</ref>, reviewed elsewhere <ref type="bibr" target="#b143">144</ref> ). According to their main biological role in inflammation, cytokines may also be subdivided as pro-inflammatory cytokines or monokines (because they are mainly produced by monocytes: IL-1 and TNF), cytokines involved in T-cell differentiation (type 1 and type 2 cytokines), and cytokines of the TGF-␤ family that promote wound healing and fibrosis. <ref type="bibr" target="#b105">106,</ref><ref type="bibr" target="#b129">130</ref> Pro-Inflammatory Cytokines. Two major molecules belong to this group: IL-1 and TNF.</p><p>IL-1 is mainly produced by activated macrophages but also by other cells such as endothelial cells. There are two functionally almost equivalent forms of IL-1, designated IL-1 ␣ and IL-1 ␤. Both forms of IL-1 bind to the same receptors (type 1 and type 2 receptors) and show similar biological activi- ties. They act on target cells both directly and via the induction of further cytokines. The main biological activity of IL-1 is the stimulation of T helper cells, which are induced to secrete IL-2 and to express IL-2 receptors. It also acts directly on B cells, promoting their proliferation and the synthesis of immunoglobulins. IL-1 also upregulates adhesion molecule expression on endothelial cells and is a strong chemoattractant for leukocytes.</p><p>Systemically, IL-1 acts as an endogenous pyrogen, and induces glucocorticoid synthesis and the release of prostaglandins, collagenase, and acute phase proteins. The synthesis of IL-1 can be induced by other cytokines, including TNF-␣ and IFN.</p><p>Two molecular species of TNF are known as TNF-␣ (cachectin) and TNF-␤ (lymphotoxin). <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> Usually the term TNF alone refers to TNF-␣. In the immune system, TNF is secreted by macrophages, monocytes, neutrophils, T cells, and NK cells following their stimulation by bacterial lipopolysaccharides. CD4 ϩ T cells but not CD8 ϩ secrete TNF-␣. Various cytokines control the production of TNF-␣: IL-2, IFN, and GM-CSF stimulate its production, whereas IL-6 and TNF-␤ inhibit it. There are two forms of TNF-␣: a transmembrane 26-kDa form and a 17-kDa secreted mature form. <ref type="bibr" target="#b42">43</ref> The multiple activities of TNF are mediated through two distinct but structurally homologous TNF receptors of 55 kDa (TNF-R1 or CD 120a) and 75 kDa (TNF-R2 or CD 120b). <ref type="bibr" target="#b102">103</ref> Although it is generally believed that TNF-R1 is responsible for most of the biological action of TNF, differential effects of the two receptor subtypes have been observed in TNF-mediated adhesion of leukocytes to the endothelium. Engagement of TNF-R1 specifically leads to the induction of the cellular adhesion molecules ICAM-1, E-selectin, VCAM1, and CD44, whereas engagement of both receptors induces ␣2 integrin expression. TNF-␣ has pleiotropic effects. It causes cytolysis of many cell types. Concerning the immune response, it induces synthesis of IL-1 and prostaglandin E2 and stimulates both the phagocytosis and the synthesis of superoxide dismutase in macrophages.</p><p>In leukocytes, TNF stimulates the expression of MHC class I and II antigen and the production of IL-1. <ref type="bibr" target="#b152">153</ref> In vivo, TNF-␣ and IL-1 are responsible for many alterations of the endothelium. <ref type="bibr" target="#b105">106</ref> Briefly, they inhibit anticoagulant mechanisms and promote thrombotic processes by inhibiting the thrombomodulin/protein C anticoagulation pathway and blocking fibrin dissolution via stimulation of the type I inhibitor of plasminogen activator.</p><p>Cytokine Involved in T-Cell Differentiation. Cytokine production during an immune response can determine the outcome of the disease. The type of antigenic-specific immune response that follows antigen administration depends upon the preferential activation of CD4 ϩ T helper (T H ) cells, which are functionally heterogeneous and consist of precursor cells (T HP ), naive cells (T H0 ), T H1 , and T H2 . <ref type="bibr" target="#b110">111,</ref><ref type="bibr" target="#b129">130</ref> T H1 and T H2 cells are derived from a common pool of precursor cells T HP which differentiate into naive T H0 cells.</p><p>The final differentiation is determined by the environment in which T H cells react to antigen stimulation; the most important cytokines that influence T H1 and T H2 differentiation are IL-12 and IL-4, respectively. The binding of cytokines to their receptors results in rapid tyrosine phosphorylation of signal transducers and activators of transcription (STATs). Consistently, deficient T H1 response is observed in knock out of the STAT4 gene and deficient T H2 response in STAT6 Ϫ/Ϫ mice. <ref type="bibr" target="#b138">139</ref> Besides, T H1 and T H2 cells show distinct and mutually exclusive patterns of cytokine secretion, T H1 cells secreting interferon-␥ (INF-␥) and IL-2, while T H2 cells produce IL-4 (Fig. <ref type="figure" target="#fig_3">4</ref>). The major physiological function of IL-2, IFN-␥ , and IL-4 are, respectively, the stimulation of T-cell proliferation, potent macrophage activation with the induction of expression for the class I and II MHC proteins, and induction of the proliferation of B cells. Therefore "delayed-type" hypersensitivity responses and pathogenic autoimmunity are mediated by T H1 cells, whereas T H2 cells mediate humoral immune responses and are associated with atopic disorders and allergic responses. <ref type="bibr" target="#b129">130</ref> Both T H1 and T H2 cells appear to regulate each other's functions. The fact that IL-4 and IL-10 produced by the T H2 cells inhibit the activities of T H1 cells, whereas IFN-␥ produced by T H1 cell suppresses the activation of T H2 cells provides an explanation for the inverse relationship observed between cell mediated and humoral responses. <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b100">101</ref> Furthermore, IL-10 is an important regulator of inflammatory and immune response. It is a powerful inhibitor of the secretion of the pro-inflammatory cytokines IL-1, TNF-␣, IL-6, and IL-8. <ref type="bibr" target="#b67">68</ref> Current concepts of autoimmune diseases focus on the disease-mediating effects of T H1 cells and the protective effects of T H2 cells. <ref type="bibr" target="#b128">129</ref> TGF-␤. TGF-␤ exists in at least five isoforms known as TGF-␤1 to 5 that are not related to TGF-␣. <ref type="bibr" target="#b134">135</ref> TGF-␤ plays a dual role during the course of inflammatory reactions, being pro-inflammatory at first and immunosuppressive later, promoting healing and development of fibrosis. <ref type="bibr" target="#b145">146</ref> TGF-␤ stimulates the synthesis of the major matrix proteins including collagen, proteoglycans, and glycosaminoglycans. It inhibits their degradation mainly by inhibiting the synthesis of neural metalloproteinases and by increasing the synthesis of proteinase inhibitors. <ref type="bibr" target="#b146">147</ref> Chemokines. Chemokines are small chemoattractant proteins of 70 -130 amino acids that are produced by leukocytes and other cells. These proteins activate G protein-coupled receptors and induce cells to migrate through a concentration gradient. Some chemokines are homeostatic in nature and are constitutively produced and secreted.</p><p>They are mainly involved in lymphocyte trafficking to lymphoid organs. <ref type="bibr" target="#b31">32</ref> We will focus on others which are considered inflammatory and only produced by cells during infection or pro-inflammatory stimuli. The role of these chemokines is to induce the migration of leukocytes to the injured site.</p><p>Structure of Chemokines and Their Receptors. Chemokines are divided into four families according to the number of cysteine residues which form disulfide bonds and the number of amino acids between the first two cysteines. Among the chemokines containing four invariant cysteine residues, there are the ␣, ␤, and ␥ group. The ␦ group formed by lymphotactin only (XCL1) contains two cysteines. <ref type="bibr" target="#b77">78</ref> Chemokines containing an amino acid between the first two cysteines are subclassified as CXC or ␣ chemokines. If the two cysteines are adjacent to each other, the chemokines are known as CC or ␤-chemokines (Table 2). Only one molecule, fraktaline, belongs to the third category: the CX3C or ␥-chemokine, which is defined by three amino acids between the first two cysteines.</p><p>The main function of CXC chemokines is to attract neutrophils to inflammatory sites whereas CC chemokines act mainly on lymphocytes and monocytes and are involved in T H1 and T H2 inflammatory responses. Therefore CC chemokines are more likely to be involved in the inflammatory response in inflammatory myopathies than CXC chemokines (the list of ␤ chemokines is reported in  Although the sequence identity among chemokines can be quite low, the overall tertiary structure is strikingly similar. <ref type="bibr" target="#b52">53,</ref><ref type="bibr" target="#b121">122</ref> The NH 2 -terminal binding site of the chemokines which represents the region of greatest variability is crucial for receptor signaling upon ligation.</p><p>For example, for the CCR2-binding CCL2 (MCP-1) the entire 10-residue N terminus preceding the first-cysteine is critical for activity. <ref type="bibr" target="#b10">11</ref> Deletion of the N-terminal glutamate results in a marked reduction in activity and deletion of the first two residues results in conversion from an agonist to an antagonist. <ref type="bibr" target="#b152">153</ref> Chemokine receptors belong to a superfamily of serpentine proteins that signal through coupled heterotrimeric G proteins. More than 20 chemokine receptors have been cloned so far. They are designated CXCR1 through 6, CCR1 through 11 (Table <ref type="table" target="#tab_1">2</ref>), XCR1, and CX3CR1 on the basis of whether they bind chemokines from the CXC, CC, C, or CX3C family.</p><p>Although each of these receptors binds only a single class of chemokines, they can bind several members of the same class with high affinity. For example, CCR1 binds CCL3 (MIP-1␣), CCL5 (RANTES), and CCL7 (MCP-3) among others, with high affinity. <ref type="bibr" target="#b118">119</ref> Conversely, several chemokines can bind and activate a number of chemokine receptors, for example, CCL3 (MIP-1␣) binds with high affinity to CCR1, CCR3, and CCR5. <ref type="bibr" target="#b98">99</ref> Major Functions of Chemokines. Chemokine receptor binding initiates a cascade of intracellular events leading to the activation not only of chemotaxis by modulating action-dependent cellular processes and up-regulating adhesion proteins, but also a wide range of functions in different leukocytes such as an increase in the respiratory burst, degranulation, phagocytosis, and lipid mediator synthesis. <ref type="bibr" target="#b10">11</ref> Although chemokines bind with their specific receptors, they also interact with other molecules that may affect their oligomeric state or activity. Cell surface and soluble glycosaminoglycans bind positively charged regions on the chemokines, specific chemokines interacting with different types of glycosaminoglycans with different affinity. <ref type="bibr" target="#b85">86</ref> In addition, oligomerization of chemokine occurs on glycosaminoglycans leading to enhanced concentrations of chemokines. <ref type="bibr" target="#b66">67</ref> Taken together, "chemokines near the sites of production may form higher order oligomers on endothelial or extracel- lular matrix glycosaminoglycans, thereby creating and presenting higher concentrations of chemokine near the initiating inflammatory or trafficking stimulus that cause the leukocyte to move up the chemokine gradient and toward the relevant site." <ref type="bibr" target="#b121">122</ref> Regulation of Chemokines and Chemokine Receptors by Cytokines. Although chemokines involved in homeostatic lymphocyte trafficking are constitutively expressed, most inflammatory chemokines are mainly induced by pro-inflammatory cytokines (IL-1␤, TNF-␣) or lipopolysaccharides. Chemokine receptor expression is also regulated by a variety of inflammatory stimuli. <ref type="bibr" target="#b137">138</ref> Treatment of freshly isolated blood T cells with IL-2 induces the expression of CCR1, CCR2, CCR5, and CXCR3 and the cells thus become responsive to the appropriate chemokines. <ref type="bibr" target="#b93">94</ref> These receptors are rapidly downregulated by stimulation with anti-CD3 and anti-CD28, which mimic the encounter with an antigen. Interestingly T H1 and T H2 showed a distinct pattern of chemokine receptor expression: CCR5 is characteristic for T H1 cells <ref type="bibr" target="#b94">95</ref> and its expression can be suppressed by IL-10, <ref type="bibr" target="#b122">123</ref> whereas CCR3 is characteristic for T H2 cells <ref type="bibr" target="#b130">131</ref> and its expression requires the synergistic effects of IL-2 and IL-4. <ref type="bibr" target="#b73">74</ref> Cell Adhesion Molecules. On the basis of their primary structure, cell adhesion molecules are divided into four families: cadherins, integrins, selectins, and the immunoglobulin superfamily.</p><p>Only molecules belonging to the last three families play a role in leukocyte migration from the vascular system to tissues. <ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b74">75</ref> There are four steps in this process which begins with the rolling of leukocytes along the vascular endothelium mediated by selectins, followed by signaling which activates leukocyte integrins (role of chemokines and their receptors), thus leading to tight adhesion to the endothelium, and finally by transmigration (integrins/ molecules of the Ig superfamily) (Fig. <ref type="figure" target="#fig_1">2</ref>).</p><p>Selectin Family. It is a small family of L-, E-and P-selectins. They are characterized by a lectin-like domain attached to an EGF-type domain and a variable number of complementary regulatory protein repeat sequences, which together comprise their extracellular motifs. <ref type="bibr" target="#b135">136,</ref><ref type="bibr" target="#b107">108</ref> P-selectin binds to P-selectin glycoprotein ligand (PSGL-1), L-selectin interacts with GlyCAM-1 and CD34, and an E-selectin monospecific ligand is E-selectin ligand (ESL-1). L-selectin is constitutively expressed by all leukocytes except activated or memory T cells. Upon leukocyte activation during rolling, L-selectin is shed rapidly from the cell surface into the circulation by cleavage at a distinct proteolytic site. <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b147">148</ref> This step is crucial and controls the time of interaction of a leukocyte with the endothelium. In contrast, P-and E-selectins are expressed by endothelial cells upon inflammatory stimuli: Pselectin is recruited to the cell surface from storage in Weibel-Palade bodies, <ref type="bibr" target="#b106">107</ref> whereas E-selectin is rapidly synthesized and transported to the cell surface upon exposure to TNF-␣, IL-1␤ and lipopolysaccharide. <ref type="bibr" target="#b86">87</ref> In contrast, antiinflammatory cytokines such as IL-4 and IL-13 can decrease the late expression of E-selectin. <ref type="bibr" target="#b51">52</ref> The inhibitory effect of IL-4 is potentiated by TGF-␤ which alone can also inhibit Eselectin expression under certain conditions. <ref type="bibr" target="#b60">61</ref> Mouse models have confirmed the crucial role of selectins in the recruitment of leukocytes from the circulation. Mutants deficient for both E-and Pselectins show a severe reduction in rolling efficiency as compared with normal mice. <ref type="bibr" target="#b57">58</ref> Integrin Family. These family members are heterodimers composed of noncovalently linked ␣ and ␤ subunits that traverse the cell membrane. There are at least 14 ␣ subunits and 8 or more ␤ subunits and thus many combinations are possible. 27,69 The association of the ␣ subunit and ␤ subunit and the presence of divalent cations are critical for ligand binding. <ref type="bibr" target="#b68">69</ref> Most of the ␤ subunits are shared by more than one ␣ subunit. The ␤1 integrins are mainly involved in tissue organization by interacting with the extracellular matrix and the basement membranes 69 except for ␣4␤1 integrin (VLA4) expressed by leukocytes. The ␤2 integrins are expressed exclusively on leukocytes and are essential for leukocyte migration to site of inflammation. 60,136 The ␤3 integrins are expressed by platelets and cells of the megakaryoblastoid lineage. <ref type="bibr" target="#b124">125</ref> The integrin ␣4␤7 is found on lymphocytes and plays a major role in the homing of intraepithelial lymphocytes to mesenteric tissue by interacting with the highly glycosylated MAdCAM-1 molecule <ref type="bibr" target="#b70">71,</ref><ref type="bibr" target="#b132">133</ref> but also in the rolling of activated T lymphocytes along MAdCAM-1. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b144">145</ref> The major ligands for the integrins fall into two categories: cell surface molecules, that are members of the immunoglobulin superfamily [such as intercellular adhesion molecules (ICAM-1, ICAM-2) interacting with most members of the ␤2 family, vascular cell adhesion molecule (VCAM-1) binding to ␣4␤1, or MAdCAM-1 interacting with ␣4␤7], and a variety of large extracellular matrix proteins (such as fibronectin, vitronectin, fibrinogen, and complementary components) (Table <ref type="table" target="#tab_3">3</ref>).</p><p>Interaction between integrins and their ligand plays a major role in the tight adhesion of leukocytes to endothelial molecules preceding transmigration. However, integrin-mediated adhesion is regulated by modulating the affinity of the integrin for its ligand or by altering the avidity of adhesion through integrin clustering and cell spreading. Interestingly, selectins play an important role in initiating the sequential adhesion cascade by increasing the ␤2 integrin adhesiveness for ICAM <ref type="bibr" target="#b133">134,</ref><ref type="bibr" target="#b142">143</ref> ; continuous migration requires a cycle of adhesion and detachment.</p><p>Whereas early adhesive interactions stimulate further integrin adhesion, engagement of integrins late in the adhesion sequence negatively feedback to promote detachment of the upstream adhesion. <ref type="bibr" target="#b149">150</ref> ␣4␤1 integrin, initiating the adhesion of leukocyte to endothelium, enhances the adhesiveness of ␣L/M␤2 integrin for ICAM-1. Conversely, both the ␤2 and ␤3 integrins downregulate adhesion of ␣4␤1 to VCAM or fibronectin. <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b71">72</ref> Chemokines play a major role in the activation of integrins (triggering) needed to stop a rolling leukocyte. Several chemokines upregulate adhesion by increasing both integrin affinity and the lateral mobility of the integrin. 31 CXCL8 (IL-8) and CCL2 (MCP-1) can trigger ␤2-integrin mediated firm adhesion of monocytes <ref type="bibr" target="#b61">62</ref> on ICAM-1 expressing cells in flow chambers. CCL21 (SLC) is the only known chemokine that can trigger ␣4␤7-integrin firm adhesion of lymphocytes to MAd CAM-1.</p><p>Moreover, chemokines regulate the order and timing of integrin adhesion. <ref type="bibr" target="#b107">108</ref> For example, it has been recently reported that CXCL1 (GRO␣) and CX3CL1 (fraktaline) mediate the initial firm adhesion whereas CCL2 (MCP-1) is required for the later step of leukocyte spreading and diapedesis. <ref type="bibr" target="#b99">100,</ref><ref type="bibr" target="#b151">152</ref> Immunoglobulin Superfamily. embers of this family show one or more of a common immunoglobulin-like repeat that is characterized by two cysteines separated by 55 to 75 amino acids. <ref type="bibr" target="#b148">149</ref> In the immune system, members of this superfamily play a critical role in cellular adhesion. Key members are ICAMs (1 to 5), which bind to LFA-1 (␣L␤2), and MAC 1 (␣⌴␤2) and MAdCAM-1, which bind to ␣4␤7.</p><p>Another member of this superfamily which exhibits homotypic molecular interaction is the platelet endothelial cell adhesion molecule-1 (PECAM-1). It plays a major role in the transmigration of leukocytes through the intercellular function of endothelial cells.</p><p>Several members of the immunoglobulin superfamily, such as ICAM-2, are constitutively expressed on endothelial cells, whereas others are expressed under inflammatory stimuli. ICAM-1 and VCAM-1 are strongly induced by pro-inflammatory cytokines, including IL-1␣, IL-1␤, TNF␣ and ␤, and various inflammatory stimuli in a wide range of cell types. 109 In contrast, TGF␤ has no effect on ICAM-1 and VCAM-1 expression in human endothelial cells. <ref type="bibr" target="#b60">61</ref> INF-␣ and IL-4 regulate the expression of either ICAM-1 or VCAM-1, respectively. MAdCAM-1 expression is also induced by pro-inflammatory cytokines but not PECAM-1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Modulation of the Expression of Cytokine, Chemokine,</head><p>and Cell Adhesion Molecules by Current Immunosuppressive Therapies. Inflammatory myopathies especially PM and DM may benefit from treatment with corticosteroids or new therapeutic regimens such as intravenous immunoglobulin and a combination of cytotoxic drugs with corticosteroids. <ref type="bibr" target="#b111">112</ref> Previous reports have shown that these immunosuppressive therapies act on various molecules involved in the inflammatory response. Besides, because numerous side effects occur with these therapeutic agents and also because some patients (especially s-IBM patients) do not respond to conventional immunotherapies, it is of utmost importance to set up new and more selective therapeutic strategies. The role of corticosteroids on the various molecules involved in the inflammatory process has been well studied in asthma. <ref type="bibr" target="#b92">93</ref> Briefly, prednisone suppresses the activation of cells producing the cytokines involved in endothelium activation (such as IL-1, TNF, IL-4, and IL-13) and in the migration of lymphocytes (such as CCL5, CCL7, and CCL11).</p><p>Intravenous immunoglobulin (IVIg) also acts on cytokine production in vitro. It inhibits the proliferation of T cells and the production of various cytokines released by these cells such as IL-2, IL-10, TNF␤ and ␣, and INF ␥, whereas it upregulates IL-1RA and IL8. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b5">6</ref> IVIg also acts on endothelial cells, which play a central role in the inflammatory process. IVIg inhibits the proliferation of endothelial cells and the production of various cell adhesion molecules such as ICAM-1, VCAM-1, chemokines, and cytokines induced by TNF-␣ or IL-1␤. <ref type="bibr" target="#b150">151</ref> Studies in chronic heart failure have shown that modulation of chemokines and chemokine receptors (CCL3, CCR1, CCL4, CCR5, and CXCR1) may also represent an important mechanism of action of IVIg. <ref type="bibr" target="#b35">36</ref> Interestingly, it has been shown that after IVIg, TGF-␤1 was downregulated in the muscle of patients with DM who had successfully responded to therapy but remained unchanged in the muscle of patients with s-IBM who did not respond. <ref type="bibr" target="#b4">5</ref> Methotrexate may also exert antiinflammatory or immunomodulatory properties by influencing the production of cytokines and other soluble mediators of inflammation, as has been shown in rheumatoid arthritis. <ref type="bibr" target="#b43">44</ref> It decreases the expression of the cyto-kines IL-1␤ and TNF-␣ and the adhesion molecules E-selectin and VCAM-1. Moreover, it has been shown that methotrexate suppressed TNF-induced NF-KB activation in Jurkat cells. <ref type="bibr" target="#b101">102</ref> All these data provide a molecular explanation of the immunosuppressive effect of corticosteroids, IVIg, and methotrexate in various autoimmune diseases. More attractive are selective treatments based on the inhibition of one molecule or its receptor. As an example, small molecule antagonists exist for several of the chemokine receptors. <ref type="bibr" target="#b52">53</ref> However, even when specific cell types are associated with a particular disease, it will be difficult to develop a single therapeutic molecule that targets the associated cell type because multiple chemokine agonists and receptors can be involved in regulating the activity of these cells. The challenge will be to identify therapeutic applications for these antagonists aimed at curing or ameliorating the effects of inflammatory myopathies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FUNCTIONAL ROLES OF CYTOKINES, CELL ADHESION MOLECULES, AND CHEMOKINES IN INFLAMMATORY MYOPATHIES</head><p>Immunological Properties of Human Myoblasts. Several studies have reported that cultured human myoblasts may express a variety of immunologically important molecules, suggesting that muscle cells largely contribute to the immune response in inflammatory myopathies. <ref type="bibr" target="#b64">65,</ref><ref type="bibr" target="#b113">114</ref> First, human myoblasts share with dendritic cells some molecules involved in antigen processing and presentation functions. Second, they constitutively express some pro-inflammatory cytokines and chemokines. Third, they may respond to inflammatory stimuli by upregulating some of these molecules but also induce the expression of new ones, including cytokines, chemokines, and cell adhesion molecules (Table <ref type="table" target="#tab_4">4</ref>).</p><p>Human Myoblasts Express Molecules Involved in Antigen Presentation. Professional antigen-presenting cells initiate the immune response by efficiently capturing small amounts of antigen from peripheral tissues and migrating to secondary lymphoid organs, where they mature and present antigenic peptides to antigen-specific T cells to initiate the expansion and maturation of helper (CD4 ϩ ) and effector (CD8 ϩ ) T cells.</p><p>Dendritic cells are the only cells that have the capacity to activate both naive and memory T cells. When they mature, they express certain molecules that play a crucial role in the activation of naive T cells. These include the peptide-loaded class I MHC, class II MHC, adhesion molecule (CD54), costimulatory molecules [B7.1 (CD80), B7.2 (CD86 and CD40)], cytokines (IL-1, IL-12) and chemokine receptors (CCR7). It has recently been shown that nonhematopoietic cells, such as muscle cells, can be engineered to present DNA-encoded antigens by coexpressing the key costimulatory molecule CD86. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b81">82</ref> Muscle fibers share with dendritic cells the expression of some cell surface molecules <ref type="bibr" target="#b116">117</ref> and likely BB-1 (a B7-related molecule that has not been molecularly defined <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b112">113</ref> ) but they do not express the costimulatory molecules (CD80/CD86). Besides, CD40 is induced on cultured myoblasts by IFN-␥ stimulation.</p><p>CD40 ligation increases IL-6, IL-8, IL-5, and CCL2 (MCP-1) production by myoblasts suggesting that interaction between T cells and muscle cells via the CD40 -CD40L system contributes to the immunopathogenesis of PM/DM by increasing inflammation via cytokine production by the muscle cells. <ref type="bibr" target="#b136">137</ref> Human Myoblasts Express Cytokines and Chemokines either Constitutively or after Cytokine Induction. Some cytokines and chemokines such as IL-6, TGF-␤, GM-CSF, CCCL5 (RANTES), and CCL3 ( MIP-1␣) are constitutively expressed by cultured human myoblasts, and the expression increases after cytokine stimulation. In contrast, other cytokines (IL-4, IL-10, INF-␥) are not expressed by human myoblasts, either constitutively or after cytokines stimulation. A third group [IL-I␤, CCL2 (MCP-1)] is observed after inflammatory stimuli only. <ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b113">114</ref> Conflicting results are reported in the literature concerning IL-1␣ and TNF-␣. Under their culture conditions, Nagaraju et al. <ref type="bibr" target="#b116">117</ref> never observed IL-1␣ expression by myoblasts whereas De Rossi et al. <ref type="bibr" target="#b40">41</ref> reported constitutive IL-␣ expression. TNF-␣ was only observed after pro-inflammatory cytokine treatment, <ref type="bibr" target="#b40">41</ref> whereas Nagaraju et al. reported constitutive mRNA expression by reverse transcriptase-polymerase chain reaction (RT-PCR). <ref type="bibr" target="#b116">117</ref> In spite of some slight differences regarding the different studies performed, all the results summarized in Table <ref type="table" target="#tab_4">4</ref> suggest that muscle fibers likely contribute to the inflammatory response in inflammatory myopathies by (1) activating memory T cells rather than naive T cells as a result of the absence of costimulatory molecule, and (2) synthesizing cytokines and chemokines, creating the conditions for chronic inflammation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expression of Cytokines, Cell Adhesion Molecules, and</head><p>Chemokines in Inflammatory Myopathies. The better characterization of the immunopathological features in inflammatory myopathies as well as the ma- </p><formula xml:id="formula_0">Ϫ Ϫ BB-1 Ϫ ϩ (INF-␥, TNF-␣, IL-4) Perpetuation of the immune response † Cytokines IL-1␣ ϩ/Ϫ † ϩ/Ϫ † IL-1␤ Ϫ ϩ IL-4, IL-10 Ϫ Ϫ IL-6 ϩ ϩ ϩ (IL-1␣, IL-1␤, TNF-␣, IFN-␥) TNF-␣ ϩ/Ϫ † ϩϩ (IL-1␣, IL-1␤, TNF-␣, INF-␥) INF-␥ Ϫ Ϫ TGF-␤ ϩ ϩ ϩ (IL-1 ␣, TNF-␣, IFN-␥) GM-CSF ϩ ϩ ϩ (IL-1 ␣, IL-1␤, TNF-␣) Chemokines CCL5 (RANTES) ϩ ϩ (INF-␥) CCL3 (MIP-1␣) ϩ ϩ ϩ (TNF-␣) CCL2 (MCP-1) Ϫ 1 (IFN-␥, TNF-␣)</formula><p>*Based on various reports and reviews. <ref type="bibr">41,65,117 †</ref> Conflicting results.</p><p>jor progress made in the understanding of the main molecular events involved in leukocytes trafficking and activation during the inflammatory process has prompted researchers to analyze the expression of these molecules in inflammatory myopathies. Although the main studies are descriptive and used various technical approaches with occasionally conflicting results, there is a consensus showing strong expression of pro-inflammatory cytokines, ␤ chemokines, and some CAM in inflammatory myopathies. Cytokine Expression. Most studies have been done in muscle presenting active myositis. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b84">85,</ref><ref type="bibr" target="#b87">88,</ref><ref type="bibr" target="#b89">90,</ref><ref type="bibr" target="#b95">96,</ref><ref type="bibr" target="#b97">98,</ref><ref type="bibr" target="#b140">141</ref> Almost all these studies showed strong expression of pro-inflammatory cytokines in all inflammatory myopathies, but the cytokine expression profile varies from one study to another. It suggests that the distinction between T H1 or T H2 related cytokines is not very clear although most studies suggest a main T H1 response.</p><p>By using RT-PCR, pro-inflammatory cytokines (IL-1␤, IL-6, and TNF-␣) were recorded in all inflammatory myopathies tested (5 DM, 3 PM, and 1 IBM), the variability of the cytokine mRNA expression being in accordance with the intensity of local inflammatory reaction, <ref type="bibr" target="#b87">88</ref> irrespective of disease activity or treatment status. <ref type="bibr" target="#b1">2</ref> In most cases, normal muscles do not show pro-inflammatory cytokine transcript. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b87">88</ref> Immunohistochemical and in situ hybridization studies further confirm these results and also show the cellular distribution of pro-inflammatory cytokines. Most studies report strong pro-inflammatory cytokine expression (IL-1␣, IL-1␤, TNF-␣) in inflammatory cellular infiltrates in all inflammatory myopathies. <ref type="bibr" target="#b97">98,</ref><ref type="bibr" target="#b140">141</ref> The strong TNF-␣ expression of infiltrating macrophages was emphasized by a few studies. <ref type="bibr" target="#b84">85,</ref><ref type="bibr" target="#b39">40</ref> Elevation of serum-soluble TNF receptors was recorded in patients presenting with PM and DM. <ref type="bibr" target="#b131">132</ref> Tews and Goebel observed that IL-1␤ expression was mainly restricted to s-IBM and observed in macrophages, whereas IL-6 expression was recorded in mononuclear cells in DM. <ref type="bibr" target="#b140">141</ref> Interestingly some studies also record pro-inflammatory cytokine expression in endothelial cells and muscle fibers.</p><p>Lundberg et al. <ref type="bibr" target="#b97">98</ref> observed that in all patients with inflammatory myopathies, endothelial cells (capillaries, arterioles, and venules) in areas surrounded by inflammatory cells but also in areas devoid of inflammation strongly expressed IL-1␣ but not IL-1␤, whereas normal endothelial cells do not express IL-1␣ and IL-1␤. Interestingly, IL-1␣ expression in endothelial cells was also observed in muscle from patients with chronic PM or DM in which inflammatory exudates were not recorded. <ref type="bibr" target="#b119">120</ref> Some authors observed both IL-1␣ and IL-1␤ immunoreactivity in endothelial cells in all inflammatory myopathies but not in normal muscles, <ref type="bibr" target="#b9">10</ref> whereas others observed constitutive expression of IL-1␣ but not IL-1␤ in endothelial cells in normal muscles. <ref type="bibr" target="#b140">141</ref> In addition, De Bleecker et al. <ref type="bibr" target="#b39">40</ref> report both TNF-␣ and TNF␣ R1 or R2 expression in endothelial cells and observed that both TNF-␣ and TNF-␣ R1 expression was higher in DM than in PM or s-IBM, suggesting a specific role of the TNF␣ pathway in endothelial degeneration in DM. Tews and Goebel observed a selective IL-1␤ expression in s-IBM both in inflammatory cells and in some muscle fibers. <ref type="bibr" target="#b140">141</ref> IL-1␣ and IL-1␤ expression were observed in all patients with DM. <ref type="bibr" target="#b9">10</ref> Furthermore, it was shown that IL-1 expression was marked in regenerative fibers and in fibers showing ischemic punched-out vacuoles that correspond to areas of myosinolysis, in atrophic perifascicular fibers, and in fibers located within healing microinfarcts, suggesting a role for IL-1 in both regeneration and myofibrillar protein breakdown in inflammatory myopathies.</p><p>Some of these reported results are somewhat conflicting, probably because of differences in the methods and antibodies used and the limited number of patients investigated. Nevertheless, these studies highlight the fact that not only inflammatory cells but also endothelial cells and muscle fibers are able to produce pro-inflammatory cytokines leading to the perpetuation of the immune response in inflammatory myopathies (Table <ref type="table" target="#tab_5">5</ref>).</p><p>The study of cytokine production in inflammatory myopathies also shows certain discrepancies, although the main cytokines recorded are IL-2 and IFN-␥ in keeping with a T H1 immune response in all inflammatory myopathy subtypes (Fig. <ref type="figure" target="#fig_4">5A</ref>). By RT-PCR, IFN-␥ was observed in 6 of 9 cases of inflammatory myopathy, IL-2 in 4, and IL-4 in only 2 cases 88 whereas, by using the same methodological approach, others 2 observed IFN-␥ in 3 of 14 cases studied, IL-2 and 3, IL-4 in 4, and IL-10 in 10 cases. No difference was observed with the subtype of inflammatory myopathy, disease activity, or treatment status .</p><p>Immunohistochemical examination revealed IL-2 expression in inflammatory exudates in 9 of 20 patients in one study <ref type="bibr" target="#b140">141</ref> but in only 1 patient of 15 in another. <ref type="bibr" target="#b97">98</ref> The authors of the latter study did not find IL-4 expression or IL-3 or IL-13 but IL-10 in 5 of 15 and GM-CSF in 8 of 15 patients. In contrast, Tews and Goebel 141 observed strong expression of IL-4 in numerous inflammatory cells in most cases (15 of  20), the expression being stronger in DM where it was recorded in all cases.</p><p>All these results suggest that in comparison with pro-inflammatory cytokines, cytokines are less expressed in inflammatory myopathies or more difficult to detect, probably because they are transiently expressed during the inflammatory process or because their production is turned off by TGF-␤, which is strongly induced and expressed in inflammatory myopathies. <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b97">98</ref> TGF␤ expression was observed in blood vessels, inflammatory cells, and the extracellular matrix. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b97">98</ref> In muscle tissue, TGF-␤1 normally exerts an antiinflammatory effect. <ref type="bibr" target="#b4">5</ref> Interestingly, in some studies the degree of TGF-␤ expression correlates with fibrosis in DM, <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b28">29</ref> and both TGF-␤ and TGF-␤ mRNA were downregulated after successful immunotherapy in biopsy specimens of patients with DM. <ref type="bibr" target="#b4">5</ref> An interesting study reported differential STAT1 expression in inflammatory myopathies, with higher expression in DM. <ref type="bibr" target="#b69">70</ref> STAT1 is upregulated after binding of cytokine (especially INF-␥ and some growth factor) with their receptors. STAT1 expression was recorded in all mononuclear cells but also in perifascicular atrophic fibers in DM, suggesting that this cytokine in conjunction with ischemia is probably involved in perifascicular muscle fiber atrophy in IBM.</p><p>It is likely that IFN-␥ plays a major role in the pathophysiology of inflammatory myopathies. This cytokine derived from activated Th cells is a strong inducer of class I MHC expression and selectively induces a T H1 immune response. Its role in polymyositis has been highlighted in experimental models. Mice lacking the suppressor of cytokine signaling [(SOCS-1) gene] may present different phenotypes according to the presence of the IFN-␥ gene. The double-mutant SOCS-1-deficient mice homozygous for IFN-␥ (SOCS-1 Ϫ/Ϫ IFN-␥ ϩ/ϩ ) develop a fatal disease with generalized tissue damage leading to macrophage infiltration and severe depletion of T and B cells. In contrast, SOCS-1 Ϫ/Ϫ IFN-␥ ϩ/ϩ mice develop profound polymyositis in skeletal and cardiac muscles with massive CD8 ϩ T lymphocyte activation and selective infiltration of the muscle tissue. <ref type="bibr" target="#b109">110</ref> Cell Adhesion Molecule Expression. Pro-inflammatory cytokine expression induces an inflammatory status that leads to an upregulation or de novo synthesis of cell adhesion molecules by endothelial cells. The interaction between endothelial cells and leukocytes depicted above allows the entry of leukocytes into muscle.</p><p>Again, most studies have shown strong expression of CAM in inflammatory myopathies (Table <ref type="table" target="#tab_6">6</ref>), but discrepancies occur and mainly concern selectin expression. Expression of E-selectin in all endothelial cells in PM and DM was recorded by some authors <ref type="bibr" target="#b72">73</ref> whereas others <ref type="bibr" target="#b27">28</ref> observed it only in arterioles and venules. E-selectin expression was not recorded in most studies. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b91">92</ref> P-selectin expression was observed in endothelial cells, expression being stronger in PM than in DM, and in venules than in arterioles. <ref type="bibr" target="#b72">73</ref> In keeping, SLe x , a common ligand for these selectins, was recorded in infiltrating leukocytes, interstitial tissues, and endothelial cells but also in some muscle fibers.</p><p>Interestingly, Tews and Goebel never observed SLe x positive leukocytes inside muscle fibers. In con-  <ref type="bibr" target="#b140">141</ref> trast, the expression of E-and P-selectin and SLe x was almost absent in normal muscles. The integrin VLA4 (␣4␤1), which initiates the adhesion of leukocyte to endothelium, was observed in leukocytes in all inflammatory myopathy subtypes <ref type="bibr" target="#b139">140</ref> and expression of its ligand, VCAM-1, was recorded not only in endothelial cells (mainly arterioles and venules) but also in perivascular leukocytes. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b91">92,</ref><ref type="bibr" target="#b139">140</ref> The integrin LFA1 (␣1␤2) which binds to ICAM-1 and 2 was strongly expressed by all inflammatory cells. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b139">140</ref> Of particular interest was the strong upregulation of ICAM-1 molecule as well as its pattern of distribution.</p><p>Endothelial cells strongly expressed ICAM-1 in all IM but the expression was stronger in endothelial cells of perimysial arterioles and venules and on some perifascicular capillaries in DM <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b139">140</ref> (Fig. <ref type="figure" target="#fig_5">6A,B</ref>). In contrast, in PM and IBM, strong ICAM-1 expression was observed on the sarcolemma of muscle cells, especially in nonnecrotic muscle fibers invaded by mononuclear cells <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b91">92</ref> (Fig. <ref type="figure" target="#fig_4">5B</ref>) suggesting that ICAM-1 not only plays a major role in leukocyte-endothelium interactions in inflammatory myopathies, with a strong upregulation in DM likely secondary to specific endothelial alterations in this disease, but also in cytotoxicity against muscle fibers by stimulating the interaction between LFA-1 positive cytokine CD8 ϩ cells with ICAM-1 expressing muscle fibers. In keeping was the correlation with the decrease in cell adhesion molecules (ICAM-1, VCAM-1, LFA-1) and also IL-1␣, IL-1␤ after corticosteroid treatment in patients with PM and DM, and the improvement of muscle function. <ref type="bibr" target="#b96">97</ref> However, by measuring soluble ICAM-1 expression in the serum of patients with PM and DM, increased expression in patients with inflammatory myopathies in compar- ison with controls was observed, <ref type="bibr" target="#b83">84</ref> but the serum level of sICAM-1 was not correlated with clinical characteristics of patients.</p><p>Chemokine Expression in Inflammatory Myopathies. Only one study has searched for ␣ chemokine [CXCL (IL-8)] expression by Western blot analysis and immunohistochemistry, and results showed no expression in any control muscles or muscles with inflammatory myopathies except a few endothelial cells. <ref type="bibr" target="#b97">98</ref> This is not surprising because CXCL8 is a chemoattractant for neutrophils, and neutrophil infiltration is not a feature of inflammatory myopathies. In contrast, most studies have reported strong expression of ␤ chemokines in inflammatory myopathies, with some discrepancies regarding ␤ chemokine expression (Table <ref type="table" target="#tab_8">7</ref>).</p><p>It appears from most studies that CCL-2 (MCP-1) probably plays a major role in the pathophysiology of all inflammatory myopathies. First, CCL-2 expression is strongly upregulated <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b90">91</ref> in comparison with normal muscle, which expresses low levels of CCL-2 by RT-PCR. <ref type="bibr" target="#b90">91</ref> Second, cellular distribution and the total amount of CCL-2 differs with the underlying disease: it is higher in DM than PM or s-IBM by RT-PCR, <ref type="bibr" target="#b90">91</ref> and mainly restricted to vessels by immunohistochemistry in DM, <ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b90">91</ref> whereas expression was strong in partial invasion in both PM and s-IBM by both in situ hybridization and immunohistochemistry (Figs. <ref type="figure" target="#fig_5">5C, 6C,D</ref>). Interestingly, in situ hybridization and immunohistochemistry has shown conflicting results regarding CCL2 expression in DM. Only endothelial cells expressed the protein whereas CCL2 mRNA was found in perivascular inflammatory cells. <ref type="bibr" target="#b90">91</ref> Surprisingly, CCL2 mRNA was not detected in DM. <ref type="bibr" target="#b37">38</ref> Although some authors <ref type="bibr" target="#b29">30</ref> reported that only vessels located near inflammatory exudates expressed CCL-2, other authors reported CCL-2 expression in all endothelial cells and vessel walls, with strongest expression in perimysial and perivascular blood vessels at sites remote from inflammatory exudates. <ref type="bibr" target="#b37">38</ref> Taken together, these data suggest that in inflammatory myopathies, CCL-2 is mainly synthesized by inflammatory cells including macrophages and Th lymphocytes, whereas synthesis by endothelial cells remains unclear; these cells, however, have the ability to concentrate CCL-2 expression, which can bind endothelial proteoglycan. Because macrophages and Th lymphocytes are producers and target of CCL-2, their recruitment in inflammatory lesions may be self-perpetuating. In both PM and s-IBM, muscle fibers contribute to the local production of CCL-2 by their ability to synthesize IFN-␥ and TNF-␣ and CD40, which induce CCL-2 expression and therefore attract the inflammatory cells. In DM, CCL-2 remains mainly in endothelial cells and smooth muscle cells. In keeping is the upregulation and the cellular distribution of CCR2, the high affinity CCL-2-specific receptor in inflammatory myopathies. CCR2 exists as two isoforms, CCR2A and CCR2B, by alternative splicing of a single gene. <ref type="bibr" target="#b24">25</ref> In inflammatory myopathies, we have observed by RT-PCR a selective upregulation of CCR2A in comparison to normal muscles, expression being higher in PM and s-IBM than in DM, whereas CCR2B expression was almost identical to controls. Interestingly, immunohistochemical analysis revealed selective expression of CCR2B by satellite cells, regenerating fibers, and end-plates, whereas CCR2A was observed in inflammatory cells and vessel walls. <ref type="bibr" target="#b14">15</ref> Moreover, CCR2A expression was much higher in inflammatory cells invading nonnecrotic muscle fibers in both PM and s-IBM but almost absent in perivascular inflammatory exudates in DM (Figs. <ref type="figure" target="#fig_5">5D, 6E,F</ref>).   This is likely because perivascular inflammatory cells are mainly formed by differentiated macrophages, together with CD4 ϩ and B lymphocytes. The differentiation of monocytes into macrophages results in an increased secretion of CCL-2, which is responsible at least in part for the downmodulation of its receptor CCR2. This results in an unresponsiveness of cells to CCL-2 providing an efficient regulatory system for controlling the extent of macrophage recruitment and activation and could explain the perivascular location of macrophage exudates in DM. <ref type="bibr" target="#b14">15</ref> Expression of other ␤ chemokines has also been reported in inflammatory myopathies. In particular, Adams et al. <ref type="bibr" target="#b1">2</ref> have shown high levels of CCL-3 (MIP-1␣) and CCL-4 (MIP-1␤) by RT-PCR. Immunohistochemical studies confirmed strong CCL-3 expression in inflammatory cells and vessels surrounded by inflammatory cells but also in extracellular matrix in all inflammatory myopathies. <ref type="bibr" target="#b29">30</ref> CCL-7 (MCP-3) and CCL-17 (TARC) were not recorded. <ref type="bibr" target="#b37">38</ref> Finally, studies of CCL-5 (RANTES) expression revealed discrepancies.</p><p>CCL-5 expression by RT-PCR was reported in most inflammatory myopathies 2 but the protein was not recorded either by immunohistochemistry or Western blot analysis. <ref type="bibr" target="#b36">37</ref> These studies further demonstrate that results of chemokine expression must be analyzed carefully because strong discordances exist regarding the expression of mRNAs or proteins.</p><p>Finally, the expression of ␤ chemokine receptors CCR1, CCR4, and CCR5 has been recently studied by immunohistochemistry and quantitative Western blot analysis. <ref type="bibr" target="#b36">37</ref> As shown in Table <ref type="table" target="#tab_1">2</ref>, CCR1 binds with high affinity numerous ␤ chemokines, including CCL-3, 5, 7, 14, 15, 16, and 23; CCR4 binds CCL-17 and 22; and CCR5 binds CCL-3, 4, and 5. Expression of these receptors was found in normal muscles. Strong upregulation of CCR4 and CCR5 were recorded in all inflammatory myopathies. The strong CCR4 expression is somewhat surprising in view of the lack of CCL-17 (TARC) expression in inflammatory myopathies, but expression of its other ligand, CCL-22, has not been studied as yet in inflammatory myopathies. In contrast, CCR1 expression was downregulated in all inflammatory myopathies. All these results require confirmation in order to evaluate the role of these chemokines and receptors in inflammatory myopathies.</p><p>Putative Sequence of Events in Inflammatory Myopathies.</p><p>Dermatomyositis. In DM, one of the upstream events is the MAC deposits within intramuscular capillaries and the strong production of proinflammatory cytokines such as TNF-␣ and IL-1, whose transcription is upregulated by hypoxia. These cytokines induce a functional program related to thrombosis and inflammation. First, these cytokines facilitate thrombus formation by inducing procoagulant activity which may be responsible for the infarcts observed in DM.</p><p>Second, the action of these cytokines is potentiated by MAC: they can induce, through activation of the nuclear transcription factor NF-Kappa B, the transcription of a number of cytokines including IL-8 and IL-1, chemokines (CCL-2) and cell adhesion molecules (E-Selectin, ICAM-1). <ref type="bibr">79 -81</ref> In keeping are the strong expression of all these molecules: TNF-␣, IL-1␣, and ICAM-1 in intramuscular capillaries in DM even in some areas without inflammation. Upregulation of CAMs and CCL-2 promote leukocyte extravasation, and the interaction between CCL-2 and their receptors is likely responsible for the perivascular exudates in DM. Besides, the complex regulation of cytokine expression is responsible for macrophage, CD4 ϩ , and B lymphocyte infiltration.</p><p>Although most authors have reported a T H1 immune response with IFN-␥ and IL-2 expression, others have suggested that IL-4, which is responsible for B cell accumulation, plays a role in DM. <ref type="bibr" target="#b140">141</ref> Both TNF-␣ and IFN-␥ are potent inducers of class I MHC. It is not surprising therefore that class I expression in DM is mainly observed in perifascicular areas whereas both TNF-␣ and MAC deposits are highly expressed. Furthermore, STAT1 expression, which is stimulated by INF-␥, was observed in perifascicular atrophic fibers in DM, <ref type="bibr" target="#b69">70</ref> suggesting that this cytokine, in conjunction with ischemia, is probably involved in perifascicular muscle fiber pathology in DM. Finally, both IL-1␣ and TNF-␣ via an effect on nitric oxid synthase synthesis 20 may be responsible for myofibrillar loss and fiber atrophy in DM.</p><p>Polymyositis and sporadic inclusion-body myositis. In contrast to DM, the primary target of the immune response in PM and s-IBM is the muscle fibers themselves. It is not clear at present if the upregulation of class I MHC expression by muscle cells is an upstream event or even a trigger event suggested in an experimental model. <ref type="bibr" target="#b115">116</ref> Nevertheless, it is worth noting that in s-IBM, class I MHC expression is found on fibers closely related to inflammatory exudates <ref type="bibr" target="#b56">57</ref> whereas almost all fibers expressed it in PM even in noninflammatory cases, <ref type="bibr" target="#b119">120</ref> suggesting that in these two diseases the mechanisms leading to class I MHC upregulation are, at least to some extent, distinct.</p><p>In both PM and s-IBM, it is likely that the production of proinflammatory cytokines especially IFN-␥ by an unknown trigger event acts directly on muscle fibers, leading to the production of molecules involved in antigen processing and presentation: muscle fibers express costimulatory molecules and make close contact with their counter receptors on the auto-invasive CD8 ϩ T cells. They also express class I MHC, LFA-3, and ICAM-1. ICAM-1 interact with LFA-1 expressed by auto-invasive T cells. Moreover, upon CD40 ligation by CD40L expressed by mononuclear cells, muscle fibers may increase the production of numerous cytokines such as IL-6, IL-8, IL-15, and CCL-2 <ref type="bibr" target="#b136">137</ref> contributing to immunopathogenesis by increasing cytokine production by muscle cells. In keeping with these results, various studies have shown the strong upregulation of CCL-2 and its receptor in partial invasion in both PM and s-IBM.</p><p>In conclusion, in spite of numerous studies showing that cytokines, chemokines, and cell adhesion molecules are involved and play a role in the pathogenesis of inflammatory myopathies, there is still a considerable lack of knowledge in these areas. In particular, it is necessary to better decipher the sequence of events involved in the production of these molecules as well as their targets and involvement in muscle fiber damage and repair, in order to offer more appropriate and selective therapy which remain hazardous in view of the complex network of molecules expressed. It will be particularly important to understand the molecular events involved at presymptomatic disease stages in order to offer the best chance of curing patients.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc>FIGURE 1. (A) Dermatomyositis, juvenile type. A massive inflammatory cell infiltrate is present in perimysial and perivascular sites. Perifascicular atrophy is prominent. [Hematoxylin and eosin (H&amp;E), original magnification ϫ130.] (B) Adult-type dermatomyositis. Large group of necrotic fibers involving a fascicle suggestive of infarct. (H&amp;E, original magnification ϫ45.) (C) Dermatomyositis, juvenile type. Immunoexpression of class I MHC antigen on the membranes of muscle fibers in perifascicular area. (Anti-class I MHC, original magnification ϫ25.) (D) Dermatomyositis, juvenile type. The membrane attack complex is localized in the vascular walls and in microthrombi of capillaries. (Anti-C5b-9, original magnification ϫ100.) (E,F) Dermatomyositis, juvenile type. Inflammatory infiltrates serial sections. Inflammatory cells are stained for B cells (CD20 ϩ ) in (C), and for helper T cells (CD4 ϩ ) in (D). (Immunohistochemistry, original magnification ϫ130.)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc>FIGURE 2. (A) Adult polymyositis. Endomysial inflammatory exudates. (H&amp;E, ϫ110.) (B) Adult polymyositis. Immunoreactivity of class I MHC on muscle fiber membranes, in regenerative fibers and nonnecrotic fibers showing partial invasion. (Anti-class I MHC, ϫ110.) (C) Adult polymyositis. Partial invasion of a nonnecrotic muscle fiber by mononuclear cells. (H&amp;E, ϫ220.) (D) Adult polymyositis. Partial invasion. Most invading cells are CD8 ϩ lymphocytes. (Anti-CD8, ϫ150.) (E) Adult polymyositis. Noninflammatory form. Rare regenerative fibers are present. (H&amp;E, ϫ110.) (F) Adult polymyositis. Noninflammatory form [same patient as in (E)]. Abnormal immunoreactivity of class I MHC is expressed on the membranes of muscle fibers and in regenerating fibers. (Anti-class I MHC, ϫ56.)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 3 .</head><label>3</label><figDesc>FIGURE 3.The major molecules involved in the four-step process leading to leukocyte transmigration.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIGURE 4 .</head><label>4</label><figDesc>FIGURE 4. Schematic representation of the differentiation of T H1 and T H2 cells from naive precursors (T HP ).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>FIGURE 5 .</head><label>5</label><figDesc>FIGURE 5. (A) Inclusion-body myositis. Immunoexpression of interferon ␥ (IFN-␥) in the mononuclear inflammatory cells of endomysial exudates and partial invasion. (Anti-IFN-␥, ϫ250.) (B) Adult polymyositis. ICAM-1 is strongly expressed on muscle-fiber cell surface, especially in fiber showing partial invasion. (Anti-ICAM-1, ϫ220.) (C) Adult polymyositis. Immunohistochemical localization of CCL2 (MCP-1). Endomysial mononuclear cells, especially cells invading nonnecrotic fibers are immunoreactive. (Anti-CCL2, ϫ220.) (D) Adult polymyositis. Numerous inflammatory cells invading nonnecrotic fibers express CCL2 receptor, CCR2A. (Anti-CCR2A, ϫ220.)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>FIGURE 6 .</head><label>6</label><figDesc>FIGURE 6. (A) Vascular expression of intercellular molecule-1 (ICAM-1) in a normal muscle. (Anti-ICAM-1, ϫ110.) (B) Adult-type dermatomyositis. ICAM-1 expression in capillaries, endothelial cells of larger vessels and inflammatory cells. Membranes of perifascicular fibers show a weak immunoreactivity. (Anti-ICAM, ϫ155.) (C) Adult-type dermatomyositis. Distribution of CCL2 (MCP-1) by in situ hybridization using an antisense probe. Positive cells are mainly located in perivascular and perifascicular exudates. (ϫ220.) (D) Adulttype dermatomyositis. MCP-1 detection concerns mainly the endothelial cells with a weak signal in the vascular walls. (Anti-CCL2, ϫ225.) (E) Adult-type dermatomyositis. Immunolocalization of CCL2 receptor (CCR2A). Only a few inflammatory cells are immmunoreactive. (Anti-CCR2A, ϫ110.) (F) Adult-type dermatomyositis. Distribution of CCR2A mRNA by in situ hybridization using an antisense probe. Positive cells are mainly located in inflammatory infiltrates. (ϫ 220.)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Main families of cytokines involved in the inflammatory process, classified according to their receptors.</figDesc><table><row><cell>General role in inflammatory process</cell><cell>Receptor family</cell><cell>Representative ligands</cell></row><row><cell>Pro-inflammatory cytokines</cell><cell>IL-1 receptor family</cell><cell>IL-1␣</cell></row><row><cell></cell><cell></cell><cell>IL-1␤</cell></row><row><cell></cell><cell></cell><cell>IL-1 receptor agonist</cell></row><row><cell></cell><cell>Class I cytokine receptors</cell><cell>IL-6</cell></row><row><cell></cell><cell>TNF receptor family</cell><cell>TNF-␣</cell></row><row><cell></cell><cell></cell><cell>TNF-␤</cell></row><row><cell>Cytokines involved in T-cell differentiation</cell><cell>Class I cytokine receptors</cell><cell>IL-2</cell></row><row><cell></cell><cell></cell><cell>IL-4</cell></row><row><cell></cell><cell></cell><cell>IL-9</cell></row><row><cell></cell><cell></cell><cell>IL-5</cell></row><row><cell></cell><cell></cell><cell>IL-13</cell></row><row><cell></cell><cell></cell><cell>IL-12</cell></row><row><cell></cell><cell>Class II cytokine receptors (interferon family receptors)</cell><cell>IFN-␥</cell></row><row><cell></cell><cell></cell><cell>IL-10</cell></row><row><cell>Cytokine involved in fibrosis</cell><cell>TGF-␤ receptors</cell><cell>TGF-␤</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 ,</head><label>2</label><figDesc>and by Olson and Ley 122 ).</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc>Nomenclature of the CC␤ chemokines and their receptors.</figDesc><table><row><cell>CC␤ chemokines</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc>Molecules involved in cell adhesion of inflammatory leukocytes.</figDesc><table><row><cell>CAMs</cell><cell>Cellular distribution of CAMs</cell><cell>Counter receptor or ligand</cell><cell>Cellular distribution of receptor</cell></row><row><cell>Selectins</cell><cell></cell><cell></cell><cell></cell></row><row><cell>E-selectin</cell><cell>Cytokine-activated endothelium</cell><cell>Sialylated Lewis-X-like structures</cell><cell>Neutrophils, some lymphocytes</cell></row><row><cell>L-selectin</cell><cell>Leukocytes (except activated or</cell><cell>GlyCAM-1 and CD34</cell><cell>Cells of high endothelial venules</cell></row><row><cell></cell><cell>memory cells)</cell><cell></cell><cell></cell></row><row><cell>P-selectin</cell><cell>Megakaryocytes, platelets,</cell><cell>PSGL-1</cell><cell>Myeloid cells and lymphoid subsets</cell></row><row><cell></cell><cell>endothelium</cell><cell></cell><cell></cell></row><row><cell>Integrins</cell><cell></cell><cell></cell><cell></cell></row><row><cell>LFA-1 (␣L ␤2)</cell><cell>Leukocytes</cell><cell>ICAM-1, ICAM-2</cell><cell>Endothelium and other cell types</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(constitutive and inducible)</cell></row><row><cell>Mac-1 (␣M ␤2)</cell><cell>Monocytes, granulocytes</cell><cell>ICAM-1, C3b, fibrinogen, factor X</cell><cell>Endothelium and other cell types</cell></row><row><cell>p150,95 (␣X␤2)</cell><cell>Monocytes, granulocytes</cell><cell>C3b, fibrinogen</cell><cell>Endothelium</cell></row><row><cell>VLA-4 (␣4␤1)</cell><cell>Lymphocytes, monocytes,</cell><cell>VCAM-1, fibronectin</cell><cell>Endothelium, macrophages, dendritic</cell></row><row><cell></cell><cell>basophils, and eosinophils</cell><cell></cell><cell>cells (constitutive and inducible)</cell></row><row><cell>LPAM-1 (␣4␤7)</cell><cell>Lymphocytes including</cell><cell>MAdCAM-1</cell><cell>Mucosal endothelium</cell></row><row><cell></cell><cell>activated T lymphocytes</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>MAdCAM-1</cell><cell>Endothelium</cell></row><row><cell>␣V␤3</cell><cell>Leukocytes</cell><cell>PECAM-1, vitronectin</cell><cell>Endothelium</cell></row><row><cell>Ig superfamily</cell><cell></cell><cell></cell><cell></cell></row><row><cell>PECAM-1</cell><cell>Leukocytes</cell><cell>PECAM-1</cell><cell>Endothelium</cell></row></table><note>CAMs, cell adhesion molecules.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4 .</head><label>4</label><figDesc>Cultured human myoblasts express (constitutively or after cytokine induction) some molecules involved in antigen presentation and perpetuation of immune response.*</figDesc><table><row><cell>Properties</cell><cell>Constitutive expression</cell><cell>Expression after cytokine or chemokine stimulation</cell></row><row><cell>Antigen processing and presentation  †</cell><cell></cell><cell></cell></row><row><cell>MHC molecules</cell><cell></cell><cell></cell></row><row><cell>MHC class I</cell><cell>(ϩ)</cell><cell>ϩ (IFN-␥, TNF-␣, IL-␣, IL-1␤, MIP-1␣, MCP-1) Ϫ(TGF-␤)</cell></row><row><cell>MHC class II</cell><cell>Ϫ</cell><cell>ϩ (IFN-␥)</cell></row><row><cell>Adhesion molecules</cell><cell></cell><cell></cell></row><row><cell>ICAM-1</cell><cell>Ϫ</cell><cell>ϩ (IFN-␥, TNF-␣, IL-␣, IL1-␤)</cell></row><row><cell>Costimulatory molecules</cell><cell></cell><cell></cell></row><row><cell>CD40</cell><cell>ϩ</cell><cell>ϩ</cell></row><row><cell>CD80 (B7.1), CD86 (B7.2)</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5 .</head><label>5</label><figDesc>Cytokine expression in inflammatory myopathies.</figDesc><table><row><cell></cell><cell>Inflammatory</cell><cell cols="3">Cell types in inflammatory myopathies</cell><cell></cell><cell></cell></row><row><cell>Cytokines</cell><cell>myopathies subtypes</cell><cell>Mononuclear cells</cell><cell>Endothelial cells</cell><cell>Muscle fibers</cell><cell>ECM</cell><cell>Reference no.</cell></row><row><cell>Pro-inflammatory cytokines</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IL-1␣</cell><cell>All</cell><cell>ϩ</cell><cell>ϩ</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>2,30,88,98,120</cell></row><row><cell>IL-1␤</cell><cell>All</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>141</cell></row><row><cell>TNF-␣</cell><cell>All</cell><cell>ϩ (PI, PM)</cell><cell>ϩ (DM)</cell><cell>ϩ (Reg)</cell><cell>Ϫ</cell><cell>2,30,85,88,98</cell></row><row><cell>IL-6</cell><cell>All</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>ϩ (Reg)</cell><cell>Ϫ</cell><cell>2,28</cell></row><row><cell>T H1 cytokines</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IL-2</cell><cell>All</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>ϩ</cell><cell>ϩ</cell><cell>2,28,141</cell></row><row><cell>INF-␥</cell><cell>All</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>ϩ</cell><cell>ϩ</cell><cell>2,28,141</cell></row><row><cell>T H2 cytokines</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IL-4</cell><cell>All (DM)*</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>2,28,141</cell></row><row><cell>IL-10</cell><cell>All</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>2,141</cell></row><row><cell>IL-13</cell><cell>-</cell><cell></cell><cell>Ϫ</cell><cell>Ϫ</cell><cell></cell><cell>141</cell></row><row><cell>TGF-␤</cell><cell>All (DM)</cell><cell>ϩ</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>ϩ</cell><cell>29</cell></row><row><cell cols="3">ECM, extracellular matrix; PI, partial invasion; Reg, regenerative fibers.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>*Conflicting results, observed in DM only.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 6 .</head><label>6</label><figDesc>CAM expression in inflammatory myopathies.</figDesc><table><row><cell></cell><cell>Inflammatory</cell><cell cols="3">Cell types in inflammatory myopathies</cell><cell></cell><cell></cell></row><row><cell></cell><cell>myopathy</cell><cell>Mononuclear</cell><cell>Endothelial</cell><cell></cell><cell>Normal</cell><cell></cell></row><row><cell>Molecules</cell><cell>subtypes</cell><cell>cells</cell><cell>cells</cell><cell>Muscle fibers</cell><cell>muscles</cell><cell>Reference no.</cell></row><row><cell>Selectins and ligands</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>E</cell><cell>All types</cell><cell>Ϫ</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>73,39,92</cell></row><row><cell>P</cell><cell>P M Ͼ DM</cell><cell>Ϫ</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>ϩ /Ϫ (few EC)</cell><cell>73</cell></row><row><cell>SLeX</cell><cell>All types</cell><cell>ϩ (except PI)</cell><cell>ϩ</cell><cell>ϩ</cell><cell>ϩ /Ϫ</cell><cell>73</cell></row><row><cell>Integrins</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>VLA-4 (␣4␤1)</cell><cell>All types</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>28,140</cell></row><row><cell>LFA-1 (␣L␤2)</cell><cell>All types</cell><cell>ϩ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>28,39,140</cell></row><row><cell>Ig superfamily</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>VCAM-1</cell><cell>All types</cell><cell>ϩ (DM)</cell><cell>ϩ</cell><cell>ϩ (regenerating perifascular</cell><cell>Ϫ</cell><cell>28,39,92,140</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>fibers)</cell><cell></cell><cell></cell></row><row><cell>ICAM-1</cell><cell>All types</cell><cell>ϩ (PI)</cell><cell>ϩ (DM 1)</cell><cell>ϩPI</cell><cell>ϩ (EC)</cell><cell>14,28,39,92,140</cell></row><row><cell cols="2">EC, endothelial cells; PI, partial invasion.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head></head><label></label><figDesc>10974598, 2003, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/mus.10462 by University Of Illinois At Urbana Champaign, Wiley Online Library on [06/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 7 .</head><label>7</label><figDesc>Chemokines and chemokine receptors expression in inflammatory myopathies.</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Inflammatory</cell><cell></cell><cell></cell><cell>Normal</cell><cell></cell></row><row><cell>Chemokines and receptors</cell><cell>Expression IM</cell><cell>Subtype</cell><cell>cells</cell><cell>Vessels</cell><cell>ECM</cell><cell>muscle</cell><cell>Reference no.</cell></row><row><cell>␤-Chemokines</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CCL2 (MCP-1)</cell><cell>1</cell><cell>DM Ͼ IBM -PM</cell><cell>ϩ (PI)</cell><cell>ϩϩ (EC)</cell><cell>ϩϩ</cell><cell>Ϫ</cell><cell>28,30,38,91</cell></row><row><cell></cell><cell></cell><cell>PM, IBM Ͼ DM</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CCR2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CCR2A</cell><cell>1</cell><cell>All</cell><cell>ϩ (PI)</cell><cell>ϩϩ</cell><cell>Ϫ</cell><cell>ϩ</cell><cell>15</cell></row><row><cell>CCR2B</cell><cell>-</cell><cell>-</cell><cell>Ϫ</cell><cell>(SMC)</cell><cell>Ϫ</cell><cell>ϩ</cell><cell></cell></row><row><cell>CCL3 (MIP-I␣)</cell><cell>1</cell><cell>All</cell><cell>ϩ</cell><cell>ϩ (EC)</cell><cell>ϩϩ</cell><cell>Ϫ</cell><cell>2,30</cell></row><row><cell>CCL4 (MIP-I␤)</cell><cell>1</cell><cell>PM Ͼ PM</cell><cell>Ϫ</cell><cell>NR</cell><cell>NR</cell><cell>Ϫ</cell><cell>2</cell></row><row><cell>CCL5 (RANTES)</cell><cell>1</cell><cell>PM Ͼ DM</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>2</cell></row><row><cell>CCL7 (MCP-3)</cell><cell>-</cell><cell></cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>38</cell></row><row><cell>CCL17 (TARC)</cell><cell>-</cell><cell></cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>38</cell></row><row><cell>␣-Chemokines</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CXCL8 (IL-8)</cell><cell>-</cell><cell></cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>Ϫ</cell><cell>38</cell></row><row><cell cols="3">EC, endothelial cells; NR, not recorded; SMC, smooth muscle cells.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="10974598" xml:id="foot_0">, 2003, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/mus.10462 by University Of Illinois At Urbana Champaign, Wiley Online Library on [06/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1">MUSCLE &amp; NERVE December 2003 10974598, 2003, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/mus.10462 by University Of Illinois At Urbana Champaign, Wiley Online Library on [06/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>This work was supported by the Association Franc ¸aise contre les Myopathies and the Programme Hospitalier de Recherche Clinique 2002. We are grateful to G. Tijeras for typing the manuscript, to M. Paul for English editing, and to L. Daniel for useful comments.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Horiuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miyake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kimura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Rev</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="5" to="19" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kirkley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eidelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dohlman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Assoc Am Physicians</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="275" to="285" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Agadjanyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Trivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Monzavi-Karbassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Nottingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dentchev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Chalian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Maldonado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">V</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Weiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="3417" to="3427" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Amemiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="2030" to="2039" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin</title>
		<author>
			<persName><forename type="first">K</forename><surname>Amemiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Semino-Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="99" to="104" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Pooled human IgG modulates cytokine production in lymphocytes and monocytes</title>
		<author>
			<persName><forename type="first">U</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bjork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Skansen-Saphir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andersson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Rev</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="21" to="42" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Appleyard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dubowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Rose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="361" to="363" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="112" to="125" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Interleukin-1 expression in inflammatory myopathies: evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Authier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mhiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chazaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Christov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cherin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Barlovatz-Meimon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gherardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathol Appl Neurobiol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="132" to="140" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Human chemokines: an update</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baggiolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dewald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Moser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="675" to="705" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Banwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1033" to="1041" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Distinct roles of Lselectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer&apos;s patch-HEV in situ: the multistep model confirmed and refined</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Bargatze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jutila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Butcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="99" to="108" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bartoccioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gallucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Scuderi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ricci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Servidei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Broccolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tonali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="166" to="172" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Civatte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="385" to="392" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="929" to="938" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions</title>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kerschensteiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Misgeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="5943" to="5951" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8ϩ T cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iglesias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dornmair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page" from="1863" to="1868" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Cachectin and tumour necrosis factor as two sides of the same biological coin</title>
		<author>
			<persName><forename type="first">B</forename><surname>Beutler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cerami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="584" to="588" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Identity of tumour necrosis factor and the macrophage-secreted factor cachectin</title>
		<author>
			<persName><forename type="first">B</forename><surname>Beutler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Greenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hulmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mathison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ulevitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cerami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="page" from="552" to="554" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes &quot;susceptible&quot; mice resistant to Leishmania major</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Bretscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Menon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">257</biblScope>
			<biblScope unit="page" from="539" to="542" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">HTLV-1 polymyositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Caldwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Breuer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Farmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Swash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="151" to="154" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Leukocyte-endothelial adhesion molecules</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Carlos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Harlan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="2068" to="2101" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Alpha 4 beta 1 integrin/ VCAM-1 interaction activates alpha L beta 2 integrin-mediated adhesion to ICAM-1 in human T cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hyduk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Cybulsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="746" to="753" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Charo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Franci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Coughlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="2752" to="2756" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="65" to="71" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The molecular structure of cell adhesion molecules</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chothia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Biochem</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="823" to="862" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IM)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Cid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Grau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Casademont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tobias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Picazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Coll-Vinent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Esparza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pedrol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Urbano</forename><forename type="middle">-</forename><surname>Marquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="467" to="473" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Transforming growth factor-beta 1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate</title>
		<author>
			<persName><forename type="first">P</forename><surname>Confalonieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cornelio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="479" to="484" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">P</forename><surname>Confalonieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Megna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galbiati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cornelio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="164" to="169" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow</title>
		<author>
			<persName><forename type="first">G</forename><surname>Constantin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Majeed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giagulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Piccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Butcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Laudanna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="759" to="769" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Chemokines and cell migration in secondary lymphoid organs</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cyster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="page" from="2098" to="2102" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Polymyositis, dermatomyositis and inclusionbody myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page" from="1487" to="1498" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The molecular and cellular pathology of inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="300" to="306" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Polymyositis associated with AIDS retrovirus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Pezeshkpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gravell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Sever</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="page" from="2381" to="2383" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Damas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gullestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Aass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Simonsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Fjeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wikeby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ueland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Eiken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Froland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Aukrust</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="187" to="193" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Beta chemokines and their receptors in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Paepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Raez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">199</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">S4</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Differential expression of chemokines in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Paepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vanwalleghem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1779" to="1785" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="369" to="376" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Meire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Declercq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Aken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="239" to="246" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation</title>
		<author>
			<persName><forename type="first">De</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Baggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De Waal Malefyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1329" to="1335" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle</title>
		<author>
			<persName><forename type="first">De</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Emslie-</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="181" to="192" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Dembic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Loetscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Gubler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Lahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gentz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brockhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lesslauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="231" to="237" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Dolhain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Tak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Dijkmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Kuiper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Miltenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="502" to="508" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">To stick or not to stick: the new leukocyte homing paradigm</title>
		<author>
			<persName><forename type="first">D</forename><surname>Dunon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Piali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Imhof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Cell Biol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="714" to="723" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies</title>
		<author>
			<persName><forename type="first">Emslie-Smith Am</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="224" to="231" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Microvascular changes in early and advanced dermatomyositis: a quantitative study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Emslie-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="343" to="356" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="209" to="215" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="704" to="721" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title level="m" type="main">The polymyositis and dermatomyositis syndrome</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
		<editor>Engel AG, Franzini-Armstrong C</editor>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>McGraw-Hill</publisher>
			<biblScope unit="page" from="1335" to="1389" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">P</forename><surname>Englund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lindroos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nennesmo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klareskog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="1263" to="1273" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">IL-4 and IL-13 downregulate rolling adhesion of leukocytes to IL-1 or TNF-alpha-activated endothelial cells by limiting the interval of E-selectin expression</title>
		<author>
			<persName><forename type="first">H</forename><surname>Etter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Althaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Eugster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Santamaria-Babi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Moser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="395" to="403" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Structure, function, and inhibition of chemokines</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lolis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Pharmacol Toxicol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="469" to="499" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: pathological changes</title>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baeta-Machado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Putzu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion body myositis and myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge, UK</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="137" to="155" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lacroix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Coquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gherardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Pathol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="279" to="284" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Expression of various isoforms of neural cell adhesive molecules and their highly polysialylated counterparts in diseased human muscles</title>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nedelec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Boucraut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bianco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rougon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="21" to="36" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Inflammatory and non-inflammatory inclusion body myositis. Characterization of the mononuclear cells and expression of the immunoreactive class I major histocompatibility complex product</title>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bianco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Devictor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="528" to="536" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Susceptibility to infection and altered hematopoiesis in mice deficient in both P-and E-selectins</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Frenette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Mayadas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Rayburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Hynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Wagner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="563" to="574" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Upregulation of Fas/Fas ligand in inclusion body myositis</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Fyhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="127" to="130" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Leukocyte adhesion-structure and function of human leukocyte beta2-integrins and their cellular ligands</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Gahmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tolvanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kotovuori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Biochem</title>
		<imprint>
			<biblScope unit="volume">245</biblScope>
			<biblScope unit="page" from="215" to="232" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Gamble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Khew-Goodall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Vadas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="4494" to="4503" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Gerszten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Garcia-Zepeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gimbrone</forename><surname>Ma</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Luster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Luscinskas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">398</biblScope>
			<biblScope unit="page" from="718" to="723" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Differential expression of perforin in muscleinfiltrating T cells in polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Engelhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pongratz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tschopp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jenne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="2905" to="2910" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Inclusion body myositis and myopathies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dimauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Rowland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="705" to="713" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<title level="m" type="main">Structural and molecular basis of skeletal muscle disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<editor>Karpati G</editor>
		<imprint>
			<date type="published" when="2002">2002</date>
			<publisher>ISN Neuropath Press</publisher>
			<biblScope unit="page" from="221" to="227" />
			<pubPlace>Basel</pubPlace>
		</imprint>
	</monogr>
	<note>Polymyositis and dermatomyositis</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="498" to="507" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Glycosaminoglycans mediate cell surface oligomerization of chemokines</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hoogewerf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Kuschert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Proudfoot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Borlat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Clark-Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Power</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Wells</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="13570" to="13578" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Biological properties of interleukin 10</title>
		<author>
			<persName><forename type="first">M</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Garra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Today</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="198" to="200" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Integrins: versatility, modulation, and signaling in cell adhesion</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Hynes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="11" to="25" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><surname>Illa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gallardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gimeno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Serrano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ferrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Juarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="81" to="88" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Leukocyte migration and adhesion</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Imhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dunon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Immunol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="345" to="416" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Cross talk between alpha(v) beta3 and alpha4beta1 integrins regulates lymphocyte migration on vascular cell adhesion molecule 1</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Imhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Weerasinghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hammel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Piali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dessing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gisler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="3242" to="3252" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Expression of selectin families and their ligand sialyl Lewis X in the muscles of inflammatory myopathies: an immunohistochemical study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Jimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wakayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Murahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yamashita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Misugi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kobayashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intern Med</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="632" to="635" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4</title>
		<author>
			<persName><forename type="first">T</forename><surname>Jinquan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Quan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Feili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Larsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Thestrup-Pedersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="4285" to="4292" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">The parting of the endothelium: miracle, or simply a junctional affair?</title>
		<author>
			<persName><forename type="first">C</forename><surname>Johnson-Leger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aurrand-Lions</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Imhof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Sci</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="921" to="933" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Pathology of the inflammatory myopathies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Baillieres Clin Neurol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="527" to="556" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Expression of immunoreactive major histocompatibility complex products in human skeletal muscles</title>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pouliot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="64" to="72" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Lymphotactin: a cytokine that represents a new class of chemokine</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Kelner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Bacon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kleyensteuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Largaespada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Copeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Bazan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Schall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">266</biblScope>
			<biblScope unit="page" from="1395" to="1399" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kilgore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Flory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Warren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="953" to="961" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kilgore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Shanley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Flory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Maheswari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Tramontini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Friedl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Warren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="2019" to="2031" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kilgore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Warren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="1434" to="1441" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Bagarazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Trivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kazahaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ciccarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Chattergoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mahalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Chalian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Agadjanyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Weiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Biotechnol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="641" to="646" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Microvascular deposition of complement membrane attack complex in dermatomyositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Kissel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Rammohan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope unit="page" from="329" to="334" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Elevated soluble intercellular adhesion molecules-1 in inflammatory myopathy</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kumamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ueyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sugihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shigenaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsuda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neurol Scand</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="34" to="37" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kuru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Inukai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Doyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Takano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sobue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="585" to="588" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Kuschert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Coulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Power</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Proudfoot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Hubbard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hoogewerf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Wells</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="12959" to="12968" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">IFN-gamma regulates the expression of the adhesion molecule ELAM-1 and IL-6 production by human endothelial cells in vitro</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Leeuwenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Asmuth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Jeunhomme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Buurman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="2110" to="2114" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Local expression of cytokines in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lepidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Frances</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Machado-Baeta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathol Appl Neurobiol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="73" to="79" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Expression of human IAP-like protein in skeletal muscle: a possible explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">The role of lymphotoxin in pathogenesis of polymyositis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Inukai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kuru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Doyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sobue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="521" to="527" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">A</forename><surname>Liprandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="642" to="648" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Expression of adhesion molecules in idiopathic inflammatory myopathies. Immuno-histochemical study of 17 cases</title>
		<author>
			<persName><forename type="first">A</forename><surname>Liprandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lepidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Pathol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="12" to="18" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Proud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Lichtenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Hubbard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Bochner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Stealey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Breslin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Freidhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Schleimer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="29" to="38" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Loetscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baggiolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Moser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="569" to="577" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">CCR5 is characteristic of Th1 lymphocytes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Loetscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uguccioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bordoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baggiolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chizzolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Dayer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">391</biblScope>
			<biblScope unit="page" from="344" to="345" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brengman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="9" to="16" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Kratz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Alexanderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Patarroyo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="336" to="348" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Ulfgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klareskog</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="865" to="874" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Chemokines-chemotactic cytokines that mediate inflammation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Luster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="page" from="436" to="445" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Differential ability of exogenous chemotactic agents to disrupt transendothelial migration of flowing neutrophils</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Luu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Rainger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Nash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="5961" to="5969" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones</title>
		<author>
			<persName><forename type="first">E</forename><surname>Maggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Parronchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Manetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Simonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Piccinni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Rugiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Carli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ricci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Romagnani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="2142" to="2147" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Aggarwal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="2911" to="2920" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">A new superfamily of cell surface proteins related to the nerve growth factor receptor</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mallett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Barclay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Today</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="220" to="223" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andreetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Baggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Oksenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Simoncini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cornelio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="2880" to="2886" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Confalonieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cornelio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">244</biblScope>
			<biblScope unit="page" from="277" to="287" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Cytokine regulation of endothelial cell function: from molecular level to the bedside</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bussolino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Introna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Today</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="231" to="240" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Mcever</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood Cells</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="73" to="80" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Leukocyte interactions mediated by selectins</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Mcever</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thromb Haemost</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="80" to="87" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Cytokine regulation of cellular adhesion molecule expression in inflammation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Meager</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine Growth Factor Rev</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="27" to="39" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-gamma and lacking the SOCS-1 gene</title>
		<author>
			<persName><forename type="first">D</forename><surname>Metcalf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Rago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mifsud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hartley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="9174" to="9179" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">The expanding universe of T-cell subsets: Th1, Th2 and more</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Mosmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Today</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="138" to="146" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">64th ENMC International Workshop: therapeutic approaches to dermatomyositis, polymyositis, and inclusion body myositis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Muller-Felber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pongratz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reimers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="88" to="92" />
			<date type="published" when="1999-01">January 1999. 2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Murata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="1660" to="1666" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Update on immunopathogenesis in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="461" to="468" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">The inhibition of apoptosis in myositis and in normal muscle cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Casciola-Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Danning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Rochon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="5459" to="5465" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Rochon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Danning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bahtiyar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Craft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hooft</forename><surname>Van Huijsduijnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="9209" to="9214" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Merritt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kirk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="407" to="414" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Villalba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Danning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tresser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fetsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="161" to="169" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor</title>
		<author>
			<persName><forename type="first">K</forename><surname>Neote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Digregorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Horuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Schall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="415" to="425" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Wikman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nennesmo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="940" to="948" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: genetic factors, aberrant protein expression, and autoimmunity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Fyhr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="469" to="475" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Chemokines and chemokine receptors in leukocyte trafficking</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Olson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Regul Integr Comp Physiol</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="R7" to="28" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Czerniewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jiyamapa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Burki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Landay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="254" to="262" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Dermatomyositis and polymyositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Civatte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chetaille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schleinitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="934" to="947" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">GPIIb-IIIa: the responsive integrin</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Charo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Scarborough</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="359" to="362" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Workshop on inflammatory myopathy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Casciola-Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="93" to="95" />
			<date type="published" when="2000-04-06">Bethesda, 5-6 April 2000. 2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases</title>
		<author>
			<persName><forename type="first">H</forename><surname>Reiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Stadecker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope unit="page" from="1369" to="1377" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory muscle disease: clinical aspects</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Rider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Baillieres Best Pract Res Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="37" to="54" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Biology of human TH1 and TH2 cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Romagnani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="121" to="129" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">The Th1/Th2 paradigm</title>
		<author>
			<persName><forename type="first">S</forename><surname>Romagnani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Today</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="263" to="266" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Sallusto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mackay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lanzavecchia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="2005" to="2007" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tomita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Son</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nishinarita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sawada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Horie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="352" to="359" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Human mucosal address in cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Shyjan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bertagnolli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Kenney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Briskin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="2851" to="2857" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Signaling functions of L-selectin in neutrophils: alterations in the cytoskeleton and colocalization with CD18</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cherapanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nadra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Waddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Doerschuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Downey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="2891" to="2901" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Transforming growth factor-beta: recent progress and new challenges</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Sporn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1017" to="1021" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="301" to="314" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sugiura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Harigai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takagi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ohta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fukasawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kamatani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="6593" to="6600" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?</title>
		<author>
			<persName><forename type="first">U</forename><surname>Syrbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Siveke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hamann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Springer Semin Immunopathol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="263" to="285" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Essential role of Stat6 in IL-4 signalling</title>
		<author>
			<persName><forename type="first">K</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Matsumoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Minami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kashiwamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakanishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kishimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Akira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="627" to="630" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Expression of cell adhesion molecules in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Tews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Goebel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="185" to="194" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Cytokine expression profile in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Tews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Goebel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="342" to="347" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">T-cell anti-apoptotic mechanisms in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tonin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Filosto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spagnolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rizzuto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tomelleri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="146" to="151" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Mechanisms that regulate the function of the selectins and their ligands</title>
		<author>
			<persName><forename type="first">D</forename><surname>Vestweber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Blanks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Physiol Rev</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="181" to="213" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<monogr>
		<title level="m" type="main">The cytokines: an overview</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vilcek</surname></persName>
		</author>
		<editor>Thomson A</editor>
		<imprint>
			<date type="published" when="1998">1998</date>
			<publisher>Academic Press</publisher>
			<biblScope unit="page" from="1" to="20" />
			<pubPlace>San Diego</pubPlace>
		</imprint>
	</monogr>
	<note>The cytokine handbook. 3rd ed</note>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">A central role for microvillous receptor presentation in leukocyte adhesion under flow</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">H</forename><surname>Von Andrian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Hasslen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Erlandsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Butcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="989" to="999" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Wahl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="61" to="74" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Transforming growth factor beta: the good, the bad, and the ugly</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Wahl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="page" from="1587" to="1590" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Neutrophil rolling altered by inhibition of L-selectin shedding in vitro</title>
		<author>
			<persName><forename type="first">B</forename><surname>Walcheck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Fisk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Payan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Feehan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Betageri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Darlak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Spatola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Kishimoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="720" to="723" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">The immunoglobulin superfamily-domains for cell surface recognition</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Barclay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="381" to="405" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Leukocyte transendothelial migration: orchestrating the underlying molecular machinery</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Worthylake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Burridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Cell Biol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="569" to="577" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Poirier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Van Huyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lucchiari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Michel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chevalier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kaveri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1257" to="1266" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zernecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Erwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Kluth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schroppel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Rees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="5755" to="5762" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<monogr>
		<title level="m" type="main">Tumor necrosis factor</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Tracey</surname></persName>
		</author>
		<editor>Thomson A</editor>
		<imprint>
			<date type="published" when="1998">1998</date>
			<publisher>Academic Press</publisher>
			<biblScope unit="page" from="517" to="548" />
			<pubPlace>San Diego</pubPlace>
		</imprint>
	</monogr>
	<note>The cytokine handbook. 3rd ed</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
